

Article

Involvement of Transporters in Intestinal Drug–Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time

David Malnoë^{1,2,3}, Olivier Fardel³ and Pascal Le Corre^{1,2,3,*}¹ Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, CHU de Rennes, 35033 Rennes, France² Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, 35043 Rennes, France³ Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)—UMR_S 1085, 35000 Rennes, France

* Correspondence: pascal.le-corre@univ-rennes1.fr

Citation: Malnoë, D.; Fardel, O.; Le Corre, P. Involvement of Transporters in Intestinal Drug–Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time. *Pharmaceutics* **2022**, *14*, 2493. <https://doi.org/10.3390/pharmaceutics14112493>

Academic Editor: Im-Sook Song

Received: 13 October 2022

Accepted: 11 November 2022

Published: 17 November 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: (1) Background: Oral targeted anticancer drugs are victims of presystemic pharmacokinetic drug–drug interactions (DDI). Identification of the nature of these DDIs, i.e., enzyme-based or/and transporter-based, is challenging, since most of these drugs are substrates of intestinal and/or hepatic cytochrome P-450 enzymes and of intestinal membrane transporters. (2) Methods: Variations in mean absorption time (MAT) between DDIs and control period (MAT ratios < 0.77 or > 1.30) have been proposed to implicate transporters in DDIs at the intestinal level. This methodology has been applied to a large set of oral targeted anticancer drugs (n = 54, involved in 77 DDI studies), from DDI studies available either in the international literature and/or in publicly accessible FDA files. (3) Results: Significant variations in MAT were evidenced in 33 DDI studies, 12 of which could be explained by modulation of an efflux transporter. In 21 DDI studies, modulation of efflux transporters could not explain the MAT variation, suggesting a possible relevant role of influx transporters in the intestinal absorption. (4) Conclusions: This methodology allows one to suggest the involvement of intestinal transporters in DDIs, and should be used in conjunction with in vitro methodologies to help understanding the origin of DDIs.

Keywords: intestinal absorption rate; t_{max} ; mean absorption time; intestinal transporters; mathematical solving; presystemic drug–drug interactions; oral targeted anticancer drugs

1. Introduction

Since dysfunctions of protein kinases are involved in the pathogenesis of several diseases, including solid or hematologic cancers and cardiovascular, autoimmune, and inflammatory diseases, protein kinase inhibitors (PKI) have triggered a large number of research programs within academia and pharmaceutical companies worldwide, leading to a regular approval of these drugs by the regulatory authorities. A list of PKIs currently in clinical trials is curated in a freely accessible database (<http://www.icoa.fr/pkldb>, accessed on 29 June 2022) [1]. Nowadays, most of the marketed PKIs are used for the treatment of various solid or hematologic cancers or directed toward inflammatory diseases. These drugs are essentially administered via the oral route, and are victims of presystemic pharmacokinetic drug–drug interactions (DDI), since most of them are substrates of intestinal and/or hepatic cytochrome P-450 (CYP) enzymes (mostly CYP3A4) and membrane transporters [2–5]. Hence, the characterization of their intestinal bioavailability, and of its factors of variability, is of critical value to optimize drug efficacy, reduce drug toxicity, and improve patient compliance.

Due to the fact that these drugs are not used via the intravenous (IV) route, and to the fact that an IV formulation is rarely available, the characterization of potential intestinal DDIs is not simple, since clearance (CL) measurements are confounded by bioavailability (F) after oral dosing. Recently, Sodhi JK and Benet LZ [6] described a powerful methodology allowing for the discrimination of changes in CL from changes in F in metabolic DDIs. This was made possible by considering that the steady-state volume of distribution (V_{ss}) remains unchanged in metabolic DDIs [7], so changes in apparent V_{ss} (V_{ss}/F) associated to changes in observed apparent clearance (CL/F) may allow one to discriminate changes in F from CL in oral metabolic DDIs. The authors indicate, however, that this method should not be used for drugs when significant systemic transporter-related DDIs are likely, because V_{ss} may be affected by such DDIs. This limitation applies to the PKIs, since most of them are both substrates of CYP450 enzymes and of transporters, leading potentially to complex DDIs.

Complex DDIs may result from different scenarios, including the concurrent inhibition of enzymes and transporters [8], leading to significant challenges for a clear identification of clinical DDIs. Indeed, alteration in the extent of bioavailability may result from metabolic-based DDI by modification in the extent of the fraction of the dose not metabolized in the intestinal (F_g) and/or in the liver (F_h) as well as from transporter-based DDIs by modification of the fraction of the dose entering the enterocyte (F_a) and/or the hepatocyte that may indirectly modify F_g and/or F_h . However, unlike metabolic DDIs, transporter-based DDIs can also result in alterations of the rate of absorption (k_a) with a decrease in absorption time (decrease in mean absorption time, MAT) linked to the inhibition of intestinal efflux transporters expressed on the apical side, and an increase in absorption time due to the induction of efflux transporter expression (increase in MAT). Based on the theory that significant intestinal transporter interactions should result in an altered rate of absorption of a victim drug, Sodhi and Benet [9] recently proposed a methodology to implicate intestinal transporters in DDI, based on data from clinical studies involving substrates of ATP-binding cassette (ABC) efflux transporters, through inhibition and/or induction of P-glycoprotein (P-gp/*ABCB1*) and/or breast cancer resistance protein (BCRP/*ABCG2*).

The aim of the current study was to apply such methodology to oral targeted anti-cancer drugs that are narrow therapeutic drugs with potentially complex DDI, to better understand the respective role of metabolism and transporters in their DDI. Data characterizing the absorption time (k_a and t_{max}) from a panel of 54 drugs were retrieved from DDI studies ($n = 101$) in published papers and/or from FDA publicly accessible files. Indeed, given that most inhibitors and inducers used in clinical DDI studies are not specific to CYP450 and transporters (or can simultaneously act on both these systems), the conclusions of some of these studies can be challenged.

2. Materials and Methods

2.1. Data Curation

Given that MAT (or k_a) was usually not available, t_{max} as well as terminal half-life ($t_{1/2}$) were retrieved when available either from data in tables or after noncompartmental pharmacokinetic analysis from digitization concentration–time profiles. AUC (area under the curve) ratios between DDIs and control periods were calculated from AUC zero-to-infinity for single-dose studies, and from AUC within the dosing interval when studies were performed at steady state. All parameters were reported as ratios from the DDI phase to control phase.

Renal and feces elimination (%), total drug and metabolite(s)), plasma protein binding (%), and blood-to-plasma ratio were also retrieved.

The data allowing for the estimation of the MAT within DDI studies were obtained either from the published literature extracted from Pubmed and/or from freely accessible Food and Drug Administration (FDA) files (section: Clinical Pharmacology and

Biopharmaceutics review from multidisciplinary review and from Labeling file) up to 29 June 2021.

2.2. Physicochemical and Biopharmaceutical Properties

The main physicochemical properties were estimated from ADMETlab 2.0 (<https://admetmesh.scbdd.com/>; accessed on 1 September 2021). The parameters are Log D (pH 7.4), Log P, topological polar surface area (TPSA in %), Log S (mol/L), and hydrogen bonding (hydrogen bond donor (HBD) and hydrogen bond acceptor (HBA)). The percentage of polar surface area was calculated from TPSA and from polar surface area (PSA in Å²) given by Dragon 6 software (Talet, Milano, Italy) [10].

pH-dependence solubility, solubility at neutral pH, and Biopharmaceutics Classification System (BCS) rating were obtained from FDA-submitted files, and classified according to the United States Pharmacopeia (USP) (i.e., very soluble, freely soluble, soluble, sparingly soluble, slightly soluble, very slightly soluble, and practically insoluble).

Membrane permeability was estimated from ADMETlab 2.0 for (Caco-2 and MDCK permeability).

Determination of the percentage of ionization and of the net charge at neutral (pH 7.40) was performed using MarvinSketch 22.2 (Chemaxon).

The concentration in the intestinal lumen at neutral pH (Ig_{ut}, mM) was estimated from the maximal solubility at neutral pH (according to USP classification, mg/mL), the usual dose per administration (mg) considering Ig_{ut} as the maximal soluble dose/250 mL.

2.3. Pharmacokinetic Properties

Absolute oral bioavailability (F_{abs}, %) and BCS data were retrieved from the FDA-submitted files, and when lacking, from the literature [11]. F_{abs} was available for only 38% of the drugs (28 of 74).

2.4. Calculation of Absorption Time

2.4.1. Mathematic Solvation in a Monocompartmental Model with Single Oral Administration

Estimation of the MAT ratio relies on a mathematical solvation using t_{1/2} and t_{max} data. Equation (1) shows the relationship between k_a, t_{max}, and k_e.

$$t_{\max} = \frac{\ln\left(\frac{k_a}{k_e}\right)}{k_a - k_e} \quad (1)$$

Equation (1): Expression of t_{max} according to a monocompartmental model with single oral administration.

From Equation (1), in order to extract k_a and express it in terms of k_e and t_{max}, the Lambert function W defined in Equation (2) must be used.

$$a \times e^a = Z \rightarrow a = W(Z) \quad (2)$$

Equation (2): Lambert function W definition.

We set:

$$a = -k_a \times t_{\max}$$

$$X = k_e \times t_{\max};$$

where X is strictly positive for t_{max} and k_e different from 0.

$$Z = \frac{-X}{e^X}$$

The Lambert function has two branches W₀ and W₋₁. Thus, for all values of Z between 0 and -1/e, W(Z) takes two solutions in the reals. For X < 1, W(Z) takes its solution in the alternative branch W₋₁, and for X ≥ 1, W(Z) takes its solution in the main branch W₀.

Equation (1) is transformed as follows to match the Lambert function expression and k_a is expressed in terms of k_e and $t_{\max}$ in the resulting Equation (3).

$$\begin{aligned} e^{(-k_a \times t_{\max})} \times (-k_a \times t_{\max}) &= \frac{-k_e \times t_{\max}}{e^{k_e \times t_{\max}}} \\ -k_a \times t_{\max} &= W\left(\frac{-k_e \times t_{\max}}{e^{k_e \times t_{\max}}}\right) \\ k_a &= \frac{W\left(\frac{-k_e \times t_{\max}}{e^{k_e \times t_{\max}}}\right)}{-t_{\max}} \end{aligned} \quad (3)$$

Equation (3): Expression of k_a according to a monocompartmental model with single oral administration using the Lambert function W .

Since the Lambert function cannot be expressed by the usual functions, it is therefore necessary to resort to approximations by sequence limit (i.e., by asymptotic expansion or by algorithmic approach).

2.4.2. Solvation of the Main Branch W_0 of Lambert Function

Halley's method makes it possible to approximate $W_0(Z)$ for all Z and for n tending towards infinity. This is a faster and more accurate generalization of Newton's method (Equation (4)). The sequence quickly converges to W_0 for n tending towards infinity [12].

$$W_{n+1} = W_n - \frac{W_n \times e^{W_n - Z}}{e^{W_n(W_n)} - \frac{(W_n + 2)(W_n \times e^{W_n - Z})}{2W_n + 2}}, W_0 = 1 \quad (4)$$

Equation (4): Estimation of $W_0(Z)$ by Halley's method that rapidly converges to $W_0(Z)$ for $n \rightarrow +\infty$ for all Z

2.4.3. Solvation of the Alternative Branch W_{-1} of Lambert Function

It is possible to approximate the W_{-1} branch of the Lambert function with precision by an algorithmic approach, which gives the Equation (5) [13].

$$W_{-1}(Z) = \ln(-Z) - 2\alpha^{-1} \times \left\{ 1 - \left[1 + \alpha \left(-\frac{1 + \ln(-Z)}{2} \right)^{\frac{1}{2}} \right]^{-1} \right\}; \text{ with } \alpha = 0.3205 \quad (5)$$

Equation (5): Estimation of $W_{-1}(Z)$ by an approximation derived from a logarithmic approach

2.4.4. Mathematic Solvation in a Monocompartmental Model with Repeated Oral Administration

$t_{\max}$ was calculated considering a monocompartmental model after repeated oral administration. Considering τ as the administration interval (h), Equation (6) shows the relationship between k_a , k_e , $t_{\max}$, and τ .

$$t_{\max} = \frac{\ln\left(\frac{k_a(1 - e^{-k_e \times \tau})}{k_e(1 - e^{-k_a \times \tau})}\right)}{k_a - k_e} \quad (6)$$

Equation (6): Expression of $t_{\max}$ according to a monocompartmental model with repeated oral administration

The expression of k_a as a function of k_e , $t_{\max}$ and τ from Equation (6) is quite complex, so it requires an approximate solution method by iteration. The algorithm written in Python for this issue is available in the Supplementary Material (Figure S1).

2.4.5. Digitalization of Concentration–Time Profiles

When $t_{1/2}$ or $t_{\max}$ were not both available, a digitization of published concentration–time profiles of victim drug was used to estimate the missing data (half-life and/or $t_{\max}$) using WebPlotDigitizer Version 4.4® (<https://automeris.io/WebPlotDigitizer/>; accessed on 20 december 2020) and subsequently analyzed using Pkanalix2020R1® (Lixoft University).

We adopted the following strategy:

1. $t_{1/2}$ and t_{max} published: solving for MAT using multiple-dose equation;
2. $t_{1/2}$ and t_{max} published: solving for MAT using simple-dose equation;
3. Data missing: noncompartmental analysis to retrieve data and solving for MAT using multiple-dose equation;
4. Data missing: noncompartmental analysis to retrieve data and solving for MAT using simple-dose equation;
5. Data missing: MAT cannot be estimated.

2.4.6. Robustness of t_{max} Estimation

MAT ratios displaying changes above 30% (i.e., MAT ratios < 0.77 or > 1.30) are considered as indicators of potentially clinically significant intestinal transporter drug–drug interactions [9].

Since the estimation of MAT is highly dependent on the quality of determination of t_{max} between the two periods of the studies (DDI and control arms), we estimated the relevance of this estimation by checking the sampling schedule used in DDI studies. Two sampling points before t_{max} value were considered relevant to estimate that t_{max} determination allowed enough precision, especially for profiles with rapid absorption.

Furthermore, a rapid analysis of the MAT estimation method showed that rather small variations of t_{max} could lead to significant variations in MAT (and MAT ratio), while variation in elimination half-life had a much lower impact on the MAT ratio. Hence, we performed simulations of MAT (and of MAT ratio) by using variation in t_{max} (from $\pm 10\%$, $\pm 25\%$ and $\pm 50\%$) reported from the different studies. These variations were applied to both t_{max} of the control period and of the DDI period using the simple-dose equation iterative solvation. We considered our estimation of MAT ratio as robust if variations from -10% to $+10\%$ in t_{max} maintained the MAT ratio outside of the range of 0.77 and 1.30.

3. Results

Among the 113 oral targeted anticancer drugs recovered from our literature search, we selected those ($n = 81$) for which sufficient data studies to allow for the estimation of MAT were anticipated, either accessible from FDA files or from the international literature. Within this set of 81 molecules, 74 had an FDA file, and their pharmacologic class (ATC5 and ATC4 classification), initial approval indication and date by the FDA and the sponsor are reported in the Supplementary Material (Table S1). Their main physicochemical and biopharmaceutic properties are presented in Table 1.

Table 1. Physicochemical and biopharmaceutic properties of 74 oral anticancer drugs. BCS (Biopharmaceutical Classification System); MW (molecular weight); nd (no data available); nHA (number of hydrogen bond acceptors); nHD (number of hydrogen bond donors); PI (practically insoluble); PSA (polar surface area); S (soluble); TPSA (topological polar surface area); VSS (very slightly soluble).

Drug	MW (g.mol ⁻¹)	LogS	USP Solubility at neu-	Solubility pH-dependent	Estimated concentration in	Ionisation at neutral pH	Net charge at pH 7.40	Caco-2 permeability (10 ⁻⁶)	MDCK permeability (10 ⁻⁶)	Fabs (%)	BCS	LogD	LogP	nHA	nHD	TPSA (Å ²)	TSA (Å ²)	%TPSA
Abemaciclib	507	-2.2	PI	yes	0.20	77.9	0.78	12.1	14.0	45	3	3.0	3.6	8	1	78	630	12.4
Acalabrutinib	466	-3.7	PI	yes	0.21	0.2	0.00	2.0	4.8	25	2	2.2	2.0	9	3	122	564	19.4
Afatinib	486	-4.5	S	yes	0.33	96.2	0.98	19.9	17.6	nd	1 or 3	3.1	3.2	8	2	92	585	14.6
Alectinib	483	-6.4	PI	yes	0.21	60.9	0.61	1.0	12.7	37	4	4.0	5.5	6	1	72	626	11.5
Alpelisib	442	-4.4	PI	yes	0.23	28.8	-0.29	13.1	13.5	nd	2	2.4	3.2	7	3	104	527	16.6
Avapritinib	499	-4.2	PI	yes	0.20	93.0	0.93	15.3	20.3	nd	2	2.5	3.6	10	2	106	590	16.9
Axitinib	387	-4.3	PI	yes	0.05	0.2	0.00	9.1	15.8	58	2	3.6	3.8	5	2	71	466	11.2
Baricitinib	371	-3.2	PI	yes	0.02	0.4	0.04	1.7	5.6	80	3	1.1	0.4	9	1	121	428	19.1
Binimetinib	441	-5.8	PI	yes	0.23	0.6	0.00	26.4	17.3	nd	nd	2.3	3.7	7	3	88	452	14.0
Bosutinib	530	-5.4	PI	yes	0.19	81.0	0.81	2.3	12.2	34	4	3.5	4.0	8	1	86	662	13.7
Brigatinib	584	-3.5	VS	no	0.82	93.2	0.93	12.2	11.0	nd	1	2.9	3.0	9	2	92	742	14.6
Cabozantinib	502	-6.6	PI	yes	0.20	3.0	0.03	5.5	15.4	nd	nd	3.4	4.3	8	2	99	818	15.7
Capmatinib	412	-4.6	nd	yes	nd	0.1	0.00	18.1	36.8	nd	2	2.7	3.1	7	1	85	463	13.5
Ceritinib	558	-4.3	PI	yes	0.18	99.8	1.00	3.2	14.9	nd	4	4.5	4.3	8	3	112	722	17.7
Cobimetinib	532	-4.7	VSS	yes	0.45	99.6	1.00	18.0	59.8	46	1	3.6	4.7	5	3	65	524	10.2
Crizotinib	450	-3.9	PI	yes	0.22	99.8	1.21	1.7	5.9	43	4	3.6	3.8	6	3	79	521	12.5
Dabrafenib	520	-4.4	PI	yes	0.19	63.7	-0.64	1.5	87.2	95	2	1.9	4.2	7	3	112	572	17.7
Dacomitinib	470	-4.3	PI	yes	0.21	93.4	0.96	5.2	24.4	80	2	3.5	4.3	7	2	83	570	13.1
Dasatinib	489	-4.3	PI	yes	0.20	38.4	0.39	13.5	12.5	nd	2	2.9	2.8	9	3	110	600	17.4
Duvelisib	417	-4.0	PI	yes	0.24	0.3	0.01	9.5	8.0	42	nd	2.9	2.7	7	2	92	468	14.6
Enasidenib	473	-3.6	PI	yes	0.21	0.0	0.00	30.9	24.4	57	nd	3.1	3.3	8	3	115	526	18.3
Encorafenib	540	-4.7	PI	yes	0.19	8.2	-0.08	1.6	13.1	nd	2	1.2	3.1	11	3	143	656	22.7
Entrectinib	561	-5.7	PI	yes	0.18	70.9	0.71	2.5	7.9	nd	2	3.8	4.9	8	3	89	671	14.1
Erdafitinib	447	-4.0	SS	yes	0.07	99.5	1.00	10.8	8.2	nd	1	3.4	4.4	8	1	77	599	12.3
Erlotinib	393	-4.7	VSS	yes	1.53	0.5	0.03	21.5	15.8	59	2	3.0	2.5	7	1	78	525	12.4
Fedratinib	525	-4.3	PI	yes	0.19	97.7	0.99	7.3	15.8	nd	nd	3.5	4.1	9	3	115	695	18.2
Fostamatinib	581	-3.0	SS	yes	0.69	100.0	-1.94	6.5	9.5	nd	nd	0.9	0.9	15	3	190	674	30.1
Gefitinib	447	-4.5	PI	yes	0.22	22.1	0.25	10.8	25.8	60	3	3.5	3.8	7	1	72	536	11.4
Gilteritinib	553	-2.4	SPS	yes	0.87	92.2	0.92	2.6	3.6	nd	nd	2.6	2.5	11	4	124	747	19.7
Glasdegib	374	-4.1	SS	yes	2.14	15.6	0.15	1.4	4.7	77	4	2.7	2.4	7	3	97	477	15.4
Ibrutinib	441	-3.4	PI	yes	0.23	0.6	0.01	3.9	9.3	nd	nd	3.4	3.2	8	2	100	539	15.8

Idelalisib	415	−3.6	PI	yes	0.24	0.2	0.00	9.5	7.7	nd	2	2.2	1.6	8	2	105	469	16.6
Imatinib	494	−3.3	VS	yes	1.62	73.5	0.74	2.7	7.3	nd	nd	3.1	3.8	8	2	90	636	14.2
Infigratinib	560	−4.6	PI	yes	0.18	87.5	0.87	18.6	19.4	nd	2	3.4	4.0	10	2	98	695	15.6
Ivosidenib	583	−4.4	PI	yes	0.17	0.0	0.00	10.0	31.5	nd	2	2.5	3.1	9	1	119	656	18.9
Lapatinib	581	−4.1	PI	nd	0.17	42.2	0.43	2.0	12.5	nd	4	3.5	4.3	8	2	110	662	17.4
Larotrectinib	428	−5.0	FS	yes	0.93	0.0	0.00	12.1	18.2	34	nd	2.8	3.3	8	2	86	494	13.6
Lenvatinib	427	−7.1	VSS	yes	0.22	1.0	0.01	5.2	7.6	nd	nd	2.9	3.1	8	4	116	494	18.3
Lorlatinib	406	−3.3	VSS	yes	0.98	2.0	0.17	2.6	7.0	81	nd	1.8	1.3	8	2	111	484	17.6
Midostaurin	571	−7.4	PI	nd	0.18	0.0	0.00	9.4	41.3	nd	2	4.0	5.5	8	1	78	632	12.3
Neratinib	557	−4.6	PI	yes	0.18	96.2	0.96	7.9	9.4	nd	nd	3.3	3.9	9	2	116	712	18.3
Nilotinib	530	−4.0	PI	yes	0.19	3.2	0.03	7.7	11.2	nd	4	3.9	4.9	8	2	101	599	16.0
Niraparib	320	−3.1	SS	no	3.75	99.8	1.00	3.2	5.0	73	2	2.3	2.3	5	3	73	398	11.6
Olaparib	435	−4.8	VSS	no	2.30	0.3	0.00	6.4	12.3	nd	4	2.2	2.2	7	1	86	511	13.7
Osimertinib	500	−4.7	VSS	yes	0.64	96.7	0.97	3.8	9.1	nd	nd	3.5	3.8	9	2	91	668	14.4
Palbociclib	448	−3.3	VSS	yes	1.12	96.7	0.97	2.6	2.4	46	2	2.5	2.2	9	2	108	563	17.2
Pazopanib	438	−4.2	PI	yes	0.23	0.2	0.01	3.2	3.0	21	nd	3.1	3.3	9	3	122	522	19.4
Pemigatinib	488	−3.9	PI	yes	0.11	3.1	0.03	7.8	20.9	nd	2	2.8	3.0	9	1	83	564	13.2
Pexidartinib	418	−4.3	PI	yes	0.24	18.7	0.19	8.8	18.5	nd	2	3.9	4.4	5	2	70	441	11.1
Ponatinib	533	−5.3	PI	yes	0.19	62.7	0.63	4.4	15.2	nd	2	4.2	5.3	7	1	66	626	10.4
Pralsetinib	533	−3.3	PI	yes	0.19	0.2	0.00	13.9	5.1	nd	2	3.3	4.0	11	3	139	675	22.0
Regorafenib	483	−6.8	PI	no	0.21	0.1	0.00	3.9	16.0	nd	2	3.6	5.3	7	3	92	517	14.7
Ribociclib	435	−1.4	VSS	yes	2.30	96.7	0.97	3.0	1.9	nd	4	2.6	2.2	9	2	94	550	15.0
Ripretinib	510	−7.4	PI	yes	0.20	2.9	0.22	4.2	13.0	nd	2 or 4	3.9	5.2	7	3	91	552	14.5
Rucaparib	323	−4.1	SS	no	7.42	98.8	0.99	3.9	9.1	36	nd	2.6	2.8	4	3	57	376	9.0
Ruxolitinib	306	−3.6	VSS	yes	0.26	0.4	0.04	19.4	5.1	nd	1	3.0	2.6	6	1	83	385	13.2
Selpercatinib	526	−3.0	VSS	yes	1.22	7.1	0.07	20.4	27.7	73	4	2.9	3.5	10	1	112	676	17.8
Selumetinib	458	−5.9	SS	yes	0.22	0.6	0.00	28.7	21.5	62	4	2.6	4.2	7	3	88	471	14.0
Sonidegib	486	−7.0	PI	no	0.21	1.1	0.01	12.9	16.5	nd	2	4.3	6.4	6	1	64	587	10.1
Sorafenib	465	−6.5	PI	yes	0.22	0.0	0.00	5.1	12.8	44	2	3.6	5.1	7	3	92	514	14.7
Sotorasib	561	−5.6	PI	yes	0.18	72.4	−0.72	11.0	31.5	nd	nd	3.5	4.4	9	1	104	697	16.6
Sunitinib	399	−2.9	S	no	0.50	97.8	0.98	3.9	11.8	nd	1	2.6	3.1	6	3	84	525	13.4
Talazoparib	380	−3.9	PI	yes	0.01	0.8	−0.01	4.5	6.3	nd	nd	2.6	2.3	7	3	89	393	14.1
Tepotinib	493	−5.2	nd	yes	nd	98.2	0.98	12.8	14.4	72	nd	3.4	4.1	8	0	97	635	15.4
Tivozanib	455	−6.0	PI	nd	0.01	14.5	−0.09	5.4	10.9	nd	nd	3.6	4.0	9	2	111	530	17.6
Tofacitinib	312	−2.2	VSS	yes	0.06	58.7	0.90	22.1	6.3	74	3	1.4	1.2	7	1	89	418	14.1
Trametinib	615	−7.6	PI	no	0.01	0.0	0.00	13.1	12.9	72	2	3.2	4.6	9	2	107	611	17.0
Tucatinib	481	−4.8	VSS	yes	2.08	52.4	0.54	10.6	10.2	nd	nd	3.1	3.9	10	2	114	567	18.1
Umbralisib	572	−3.6	PI	yes	0.17	0.5	0.01	8.0	12.1	nd	2	3.7	4.7	8	2	110	636	17.4
Upadacitinib	380	−3.8	VSS	yes	0.16	0.0	0.00	17.0	10.2	nd	nd	2.7	2.2	7	2	78	418	12.4
Vandetanib	475	−4.3	PI	yes	0.21	98.2	0.98	9.1	17.9	nd	2	3.6	4.3	6	1	63	530	10.0
Vemurafenib	490	−6.2	PI	yes	0.20	3.3	−0.03	3.5	14.5	nd	4	3.6	5.3	6	2	92	526	14.6
Vismodegib	421	−5.6	PI	yes	0.24	0.0	0.00	20.6	15.5	32	2	3.1	3.7	5	1	76	468	12.1

Zanubrutinib	472	−5.2	PI	yes	0.21	100.0	0.00	2.7	10.3	nd	nd	3.3	3.2	8	3	102	596	16.3
Mean	473	−4.5	-	-	0.6	40.9	0.3	9.2	15.1	-	-	3.0	3.5	8	2	96	566	15.3
SD	70	1.3	-	-	1.1	42.9	0.5	7.1	12.7	-	-	0.7	1.2	2	1	21	97	3.4

Besides the 71 kinase inhibitors within this set of 81 molecules, 10 drugs with similar physicochemical properties are included (i.e., inhibitors of isocitrate dehydrogenase enzyme IDH-I (n = 2: enasidenib, ivosidenib), hedgehog pathway inhibitors HP-I (n = 3: glasdegib, sonidegib, vismodegib), and poly(ADP-ribose) polymerase inhibitors PARP-I (n = 5: niraparib, olaparib, pamiparib, rucaparib, talazoparib)).

From this set of 81 molecules, DDI studies involving either rifampin (RIF), itraconazole (ITRA), or ketoconazole (KETO) with sufficient information to evaluate MAT ratio were found for 54 molecules involved in 101 DDI studies.

3.1. Physicochemical and Biopharmaceutical Properties

The solubility characterization was based on the values of the solubility reported at neutral pH and classified according to the USP classification. The distribution of the solubility is illustrated in Supplementary Material (Figure S2.). Two-thirds of the compounds (n = 47) have a solubility rated as practically insoluble (PI, i.e., <0.1 mg/mL), and 88% (n = 65) have a pH-dependent solubility. Hence, most of these compounds (92%, n = 68) were rated as BCS class-2, BCS class-4, or BCS class-2/4.

The mean MW (479 ± 83 daltons), TPSA (97.3 ± 22.8 Å), and Log P (3.6 ± 1.2) were close to the mean values calculated from a large database of PKIs either approved or in clinical trials (MW: 463 daltons, TPSA: 96.6 Å and Log P: 3.5 [14]). The mean ($\pm$ SD) in silico-estimated Caco-2 and MDCK cell permeability was $9.1 \pm 7.1 \times 10^{-6}$ and $15.3 \pm 12.6 \times 10^{-6}$ cm/s, respectively.

Data reported in Table 1 show that the oral absolute bioavailability was only available for a relatively small number of molecules (i.e., 28/74 molecules). The mean absolute bioavailability was quite large, with a significant variability (mean $\pm$ SD: $56 \pm 20\%$).

PCA analysis showed that the principal components F1 and F3 explained 51.2% of the total data variance in descriptors from the original data set. The variables most correlated to F1 were Log D and Log P (positive correlation), whereas TPSA and %TPSA were negatively correlated to F1 (Figure 1). With regard to the second component (F3), we observed that Fabs was not surprisingly positively correlated with membrane permeability and solubility, and negatively correlated to HBD. However, the absolute values of coefficient of correlations were somewhat small (around 0.5, Table 2). The other variables had a low contribution to Fabs (lower than 6%).




Figure 1. Ordination biplots of principal component analysis (PCA) outputs of the physicochemical space in a series of oral targeted anticancer drugs ($n = 28$).

Table 2. Characteristics of principal component analysis (PCA). The left side of the table presents the relative contributions of the different variables to the main components (PC1 and PC3). The right side of the table presents the corresponding absolute values of coefficient of correlation indicating the strength of correlation.

	Contribution of Variables (%)		Absolute Value of Coefficient of Correlation	
	F1	F3	F1	F3
HBD	1.56	11.23	−0.240	−0.402
HBA	9.38	0.15	−0.588	−0.046
TPSA	19.25	2.63	−0.842	−0.195
%TPSA	20.00	5.79	−0.859	−0.289
LogS	10.45	3.54	−0.621	0.226
LogD	20.10	2.79	0.861	−0.200
LogP	16.14	0.67	0.771	−0.098
Caco-2 permeability	0.43	15.58	0.126	0.474
MDCK permeability	0.11	16.42	0.064	0.486
Fabs (%)	2.58	41.20	−0.308	0.770

3.2. Drug–Drug Interactions

Based on the DDI-to-control AUC ratio, the intensity of metabolic inhibition (in KETO and ITRA DDI studies) and of metabolic induction (in RIF DDI studies) appeared related. This relationship was more pronounced between KETO and RIF studies ($R^2 = 0.7160$, Figure 2B) than between ITRA and RIF studies ($R^2 = 0.2967$, Figure 2A).




Figure 2. Magnitude of the DDI (estimated by the DDI-to-control AUC ratio) in inhibition DDI studies (with KETO or ITRA) as a function the magnitude of the DDI in induction DDI studies (RIF). **(A):** itraconazole DDI study versus rifampin DDI study. **(B):** ketoconazole DDI study versus rifampin DDI study. The coefficient of determination R^2 is indicated for each relationship; the 95% confidence interval is represented on each plot.

The magnitude of the effect of a DDI on the systemic exposure (estimated by the DDI-to-control AUC ratio) with ITRA and KETO decreased with the increase in oral Fabs in a series of drugs including dual substrates of CYP3A4/P-gp (acalabrutinib, axitinib, bari-citinib, bosutinib, crizotinib, dabrafenib, duvelisib, erlotinib, gefitinib, glasdegib, larotrec-tinib, lorlatinib, palbociclib, selpercatinib and tofacitinib) and tazoloparib (P-gp substrate and minimally metabolized). However, the correlation was moderate ($R^2 = 0.5835$), as a result of a rather “flat” relationship for drugs with Fabs ranging 40 to 80% (Figure 3B).

The intensity of the DDI with rifampin (as multiple doses) was apparently not influ-enced by the intensity of Fabs, with DDI-to-control AUC ratio lower than 0.4 for drugs with oral Fabs up to 80% (Figure 3A).




Figure 3. Magnitude of the DDI (estimated by the DDI-to-control AUC ratio) as a function of the oral absolute bioavailability (Fabs, %) (A): rifampin DDI studies (blue circle). (B): ketoconazole DDI studies (red square) and itraconazole DDI studies (green triangle). The coefficient of determination R^2 is indicated for each relationship, and the 95% confidence interval is represented on each plot.

The magnitude of the effect of a DDI on the absorption rate (estimated by MAT ratio) appeared linked to the intestinal bioavailability (Fabs), both in inhibition and induction DDI studies (Figure 4). In inhibition DDI studies (using ITRA or KETO), the MAT ratio tended to decrease when Fabs decreased for a series of drugs, including dual CYP3A4/P-gp substrates (acalabrutinib, bosutinib, gefitinib, lapatinib, larotrectinib, lorlatinib, palbociclib and pazopanib), and talazoparib (P-gp substrate and minimally metabolized) and alectinib (CYP3A4 substrate and not substrate for P-gp and BCRP). In induction DDI studies (using RIF), the MAT ratio tended to increase when Fabs decreased.




Figure 4. Magnitude of the DDIs (estimated by the DDI-to-control AUC ratio) from KETO and ITRA DDI studies in a series of oral targeted anticancer drugs. The means $\pm$ SD of DDI-to-control AUC ratio for KETO and ITRA was 3.73 ± 4.34 ($n = 29$) and 3.48 ± 2.90 ($n = 21$).

3.3. Drug–Drug Interactions

Finally, we found 54 drugs for which a DDI study with a perpetrator potentially interacting with a transporter (i.e., RIF $n = 44$, KETO $n = 25$, ITRA $n = 22$, and miscellaneous drugs $n = 10$) was available (see flow-chart in Figure 5).




Figure 5. Flow-chart of the studies with potential implication of efflux and influx transporters in DDIs at the intestinal level for oral targeted anticancer drugs.

For 14 of these drugs, involved in 24 DDI studies, there was apparently no modification of the absorption rate (MAT ratio between 0.77 and 1.30), and in most of the DDI studies ($n = 20/24$), there was no modification in t_{max} (t_{max} ratio = 1, Table 3 bottom).

The top of Table 3 indicates the drugs ($n = 40$) for which a variation in MAT has been estimated during a DDI study involving either RIF ($n = 33$), KETO ($n = 20$), ITRA ($n = 15$),

or with a miscellaneous perpetrator ($n = 9$). In this series, the BCS classification of the drugs for which a transporter-based DDI was suggested ($n = 27$) was: BCS class-2 (30%), BCS class-4 (26%), BCS class-1 (11%), BCS class-3 (26%), and unknown BCS class (26%).

Given that the estimation of MAT is sensible to variations in the determinations of t_{max} , rather than variations in $t_{1/2}$ (Figure 6), we decided to add a robustness test by simulating the impact of variations (from $\pm 10\%$, $\pm 25\%$ and $\pm 50\%$) in the estimated t_{max} values obtained for both the control and the DDI arms of the studies, even though the MAT ratio was found significant (i.e., >1.30 or <0.77). If the lowest variation ($\pm 10\%$ in t_{max}) led to a shift in MAT ratio inside the 0.77-to-1.30 range, the robustness of the estimation of the MAT ratio was considered insufficient as a reliant marker of a variation in absorption rate. This can be illustrated by ceritinib in the rifampin DDI study, where the MAT ratio (0.74) shifted into the 0.77-to-1.30 interval. Thus, even if the MAT ratio was <0.77 , it was not considered robust enough to be evidence of a variation in the absorption rate. Conversely, considering the rifampin DDI study with palbociclib, the MAT ratio (0.39) remained lower than 0.77, even with variations in t_{max} up to $\pm 50\%$. The results of the simulations of the variations in t_{max} made for each individual drug are illustrated in Supplementary Material (Figure S3.).




Figure 6. Influence of variations in t_{max} (h) and in $t_{1/2}$ (h^{-1}) on the estimation of k_a . Small variations in t_{max} have greater impact on k_a than variations in $t_{1/2}$, especially when t_{max} value are small.

As whole, from 54 DDI studies leading to a MAT ratio >1.30 or <0.77 , only 33 of them had a MAT ratio unaffected (i.e., always remaining >1.30 or <0.77) by variations of $\pm 10\%$ in t_{max} , and were thus considered as potentially resulting from a variation in the absorption rate. The magnitude of the effect of a DDI on the absorption rate of a drug (estimated by MAT ratio) appeared related to the Fabs of the drugs (Figure 7).




Figure 7. The magnitude of the effect of a DDI on the absorption rate of a drug (estimated by MAT ratio) as a function of the absolute bioavailability (Fabs) in a series of oral targeted anticancer drugs. (A): inhibition DDI studies (KETO-ITRA-POSA). (B): induction DDI studies (RIF). The coefficient of determination R^2 and the P value on the linear correlation is indicated for each relationship, and the 95% confidence interval is represented on each plot.

Table 3. Involvement of efflux intestinal transporters in DDI studies [15–109].

Drug	Substrate	Inducer	Inhibitor	BCS	F (%)	Population	Perpetrator	Victim drug dosing (mg)	AUC- DDI/AUC- Control	Control or DDI period	Tmax	t1/2,z	MAT	MAT calculation method	Tmax ratio	t1/2,z ratio	MAT ratio	Absorption rate (ka)	Potential DDI mechanism at enterocyte level	References
Top																				
Abemaciclib	Enzyme CYP3A4	-	-							Control	8.0	38.6	2.43							
	Transporter Pgp and BCRP	-	P-gp, BCRP, OCT2, MATE1 and MATE2-K	3	45	HS/25	Rifampin	200	0.05	DDI	8.2	12.6	4.33	d	1.02	0.33	1.78	↓	Efflux induction	[15,16]
Acalabrutinib	Enzyme CYP3A4	CYP1A2, CYP2B6 and CYP3A4	CYP3A4/5, CYP2C8 and CYP2C9	2	25	HS/16	Itraconazole	50	5.20	Control	0.6	0.7	0.35							
	Transporter P-gp and BCRP	nd	BCRP			HS/24	Rifampin	100	0.23	DDI	0.5	1.4	0.21	d	0.93	1.92	0.61	↑	Efflux inhibition	[17,18]
Alectinib	Enzyme CYP3A4	-	nd	4	37	HS/16	Rifampin	600	0.26	Control	6.0	19.2	2.17	b	0.67	0.57	0.71	NS	-	[19,20]
	Transporter -	-	P-gp and BCRP			HS/24	Posaconazole	300	1.75	DDI	8.0	18.4	3.39	b	1.00	1.35	0.87	NS	-	
Alflutamide	Enzyme CYP3A4	CYP3A4	-	nd	nd	HS/30	Rifampin	80	0.13	Control	4.0	37.1	0.98	b	0.50	0.42	0.53	↑	Influx induction	[21]
	Transporter -	nd	nd			HS/30	Itraconazole	400	2.39	DDI	2.0	15.7	0.52	b	2.00	1.73	2.08	↓	Influx inhibition	[22]
Avapritinib	Enzyme CYP3A4 and CYP2C9	CYP3A4	CYP3A4 and CYP2C9	2	nd	HS/nd	Itraconazole	200	4.20	Control	9.7	56.7	2.77							
	Transporter -	-	P-gp, BCRP, MATE1,							DDI	5.5	183.4	0.98	d	0.57	3.24	0.35	↑	Efflux inhibition	[23]

Cobimetinib	Enzyme	CYP3A and UGT2B7	nd	CYP3A and CYP2D6	1	46	HS/15	Itraconazole	10	6.72	Control	2.0	56.8	0.37	d	2.00	2.64	1.89	↓	Influx inhibition	[33,34]
	Transporter	P-gp	nd	nd							DDI	4.0	150.0	0.69							
Crizotinib	Enzyme	CYP3A4/5	-	CYP3A	4	43	HS/15	Rifampin	250	0.18	Control	5.0	33.1	1.36	b	0.60	1.46	0.46	↑	Influx induction	[35]
	Transporter	P-gp	-	P-gp			HS/15	Ketoconazole	150	3.16	Control	5.0	37.1	1.31	b	1.20	1.48	1.12			
Dabrafenib	Enzyme	CYP3A4 and CYP2C8, CYP2C9, CYP2C19, and UDP glucuronosyltransferases	nd		2	95	P/15	Ketoconazole	75	1.71	Control	1.1	1.9	0.55	c	1.82	1.17	2.53	↓	Influx inhibition	[36,37]
	Transporter	P-gp and BCRP	nd	OATP1B1, OATP1B3, OAT1/3 and BCRP							DDI	2.0	2.3	1.39							
Dacomitinib	Enzyme	CYP2D6 and CYP2C9, CYP3A4	-	CYP2D6 and UGT1A1	2	80	H/14	Paroxetine	45	1.37	Control	10.0	90.1	2.48	b	0.80	1.07	0.74	NS	-	[38,39]
	Transporter	P-gp and BCRP	nd	P-gp, BCRP and OCT1							DDI	8.0	96.2	1.82							
Dasatinib	Enzyme	CYP3A4	nd	nd	2	nd	P/18	Ketoconazole	20	4.84	Control	0.4	3.3	0.09	c	4.03	2.64	4.93	↓	Influx inhibition	[40,41]
			nd				HS/20	Rifampin	100	0.18	Control	1.0	4.7	0.31	b	1.00	0.72	1.14			

	Transporter	P-gp and BCRP	P-gp and BCRP OATP1B1 /1B3						DDI	1.0	3.4	0.35									
Entrectinib	Enzyme	CYP3A4	-	CYP3A4		P/10	Rifampin	600	0.23	Control DDI	5.0 0.7	15.5 4.5	1.81 0.20	d	0.15	0.29	0.11	↑	Influx induction	[42,43]	
				P-gp, BCRP, OATP1B1, and MATE1	2	nd				Control	1.6	20.1	0.36								
	Transporter	P-gp (weak)	-			P/10	Itraconazole	100	6.04	DDI	4.6	55.5	1.06	b	2.90	2.76	2.94	↓	Influx inhibition	[42]	
Fedratinib	Enzyme	CYP3A4, CYP2C19	nd	CYP3A4, CYP2D6 and CYP2C19		HS/7	Ketoconazole	300	3.06	Control DDI	3.0 2.5	77.0 95.0	0.56 0.43	b	0.83	1.23	0.77	NS	-		
				P-gp, BCRP, OATP1B1, OATP1B3, OCT2, MATE 1 and MATE-2K	2	nd				Control	1.5	112.0	0.23								
	Transporter	P-gp	nd			HS/7	Ketoconazole	50	3.85	DDI	1.5	131.0	0.22	b	1.00	1.17	0.97	NS	-	[44,45]	
Fuzuloparib	Enzyme	CYP3A4 and CYP3A4	nd	CYP1A2, CYP2B6 and CYP3A4	nd	nd	HS/16	Rifampin	50	0.11	Control	3.0	10.8	1.03	b	0.67	0.19	1.35	NS	-	[46]
	Transporter	nd	nd	nd						DDI	2.0	2.1	1.39								
Glasdegib		CYP3A4, CYP2C8 and UGT1A9	-	-						Control	1.0	18.3	0.20								
	Enzyme					HS/14	Ketoconazole	200	2.40	DDI	2.0	20.0	0.48	b	2.00	1.09	2.35	↓	Influx inhibition	[47]	
					4	77															
	Transporter	P-gp and BCRP	-	P-gp, BCRP, MATE1 and		HS/12	Rifampin	100	0.30	Control DDI	1.5 1.3	13.4 5.1	0.37 0.41	b	0.83	0.38	1.10	NS	-	[47,48]	

MATE-2K																					
Ibrutinib	Enzyme	CYP3A4 and CYP2D6	nd	nd	nd	nd	HS/11	Itraconazole	140	10.00	Control	2.0	4.7	0.84					↓	Influx inhibition	[49]
	Transporter	nd	nd	P-gp (GIT)			HS/18	Ketoconazole	120	23.90	Control DDI	1.4 1.9	2.6 4.6	0.69 0.80	b	1.50	0.81	2.17			
Idelalisib	Enzyme	Aldehyde oxidase, CYP3A4 and UGT1A4	nd	nd	2	nd	HS/12	Rifampin	150	0.24	Control	1.8	5.8	0.62					↓	Efflux induction	[51]
	Transporter	P-gp and BCRP	nd	P-gp - OATP1B1-1B3						DDI	1.5	1.8	0.96	b	0.86	0.31	1.53				
Lapatinib	Enzyme	CYP3A4, CYP3A5, CYP2C19 and CYP2C8	nd	CYP3A4	4	25	HS/20	Ketoconazole	100	3.57	Control	4.0	9.6	1.66					NS	-	[52,53]
	Transporter	P-gp and BCRP	nd	P-gp and BCRP			HS/23	Carbamazepine	250	0.28	Control DDI	4.0 3.0	10.2 10.0	1.61 1.07	b	0.75	0.98	0.66			
Larotrectinib	Enzyme	CYP3A4	-	-			HS/12	Rifampin	100	0.19	Control DDI	1.0 0.5	2.9 1.2	0.39 0.19	d	0.46	0.41	0.49	↑	Influx induction	[54,55]
		P-gp and BCRP			1	34	HS/12	Rifampin - SD	100	0.19	Control DDI	1.0 1.0	2.9 1.9	0.39 0.48	d	0.99	0.66	1.22	NS	-	
	Transporter	P-gp and OATP1A2 (weak)	-	-							Control	0.9	2.5	0.37					↑	Efflux inhibition	[55]
							HS/12	Itraconazole	100	4.30	DDI	0.8	7.7	0.20	d	0.89	3.11	0.56			
		CYP3A	nd	nd			HS/14	Rifampin	24	0.82	Control	2.0	22.0	0.47	b	1.25	0.82	1.42	NS	-	[56,57]

Lenvatinib	Enzyme	CYP3A and aldehyde oxidase	nd	CYP2C8, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A and UGT1A1	nd	nd	HS/15	Rifampin - SD	24	1.36	Control	DDI	2.5	18.2	0.68	b	1.00	0.98	0.99	NS	-	
Motesanib	Enzyme	nd	nd	nd	nd	nd	P/12	Ketoconazole	50	1.66	Control	DDI	2.0	21.5	0.48	a	0.85	1.38	0.73	NS	-	[57]
Nilotinib	Enzyme	CYP3A4	nd	CYP3A4/5, CYP2C8, CYP2C9, CYP2D6, and UGT1A1	4	nd	HS/15	Rifampin	400	0.20	Control	DDI	3.0	18.6	0.84	b	1.33	0.78	1.63	↓	Efflux induction	[59,60]
Olaparib	Enzyme	CYP3A	CYP3A - CYP2B6	CYP3A - UGT1A1	4	nd	P/18	Rifampin	300	0.13	Control	DDI	1.5	13.2	0.37	b	0.53	1.20	0.42	↑	Influx induction	[61,62]
Palbociclib	Enzyme	CYP3A4 -	-	CYP3A (tile-dep)	2	45.7	HS/12	Itraconazole	125	1.87	Control	DDI	8.1	22.1	3.14	b	0.91	1.54	0.73	NS	-	[63,64]

		SULT2A1																		
										Control	8.0	22.6	3.06							
	Transp orter	P-gp and BCRP	-	P-gp, BCRP and OCT1 - OAT1, OAT3, OCT2, OATP1B1 /3 (low)		HS/15	Rifampin	125	0.16	DDI	3.0	7.8	1.20	b	0.38	0.34	0.39	↑	Influx induction	
Pamipa rib	Enzym e	CYP3A and 2C8	nd	nd	nd	nd	P/12	Itraconaz ole	20	0.99	Control	2.0	9.3	0.62						
										DDI	1.0	11.2	0.23	b	0.50	1.20	0.37	↑	Efflux inhibition	[65]
	Transp orter	-	nd	nd			P/11	Rifampin	60	0.57	Control	2.0	13.4	0.543						
										DDI	2.0	7.7	0.67	b	1.00	0.57	1.23	NS	-	
Pazopa nib	Enzym e	CYP3A 4, CYP1A 2 and CYP2C 8	CYP3A4 and CYP2B6	CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19 / CYP2D6, CYP2E1, CYP3A4, UGT1A1	nd	21	P/16	Ketocona zole	400	1.66	Control	4.0	41.5	0.94						
														c	0.87	3.91	0.61	↑	Efflux inhibition	[66,67]
	Transp orter	P-gp and BCRP	nd	OATP1B1						DDI	3.5	162.3	0.58							
Pexidar tinib	Enzym e	CYP3A 4 and UGT1 A4	CYP2B6	CYP2B6			HS/16	Rifampin	600	0.37	Control	2.5	24.2	0.61						
										DDI	3.0	16.8	0.87	b	0.80	1.19	1.43	NS	-	
	Transp orter	-	-	MATE1, MATE2- K, OATP1B1 / OATP1B3	2	nd	HS/16	Itraconaz ole	600	1.73	Control	2.5	24.2	0.61						
										DDI	2.0	28.8	0.43	b	0.80	1.19	0.72	NS	-	[68]

Pyrothinib	Enzyme	CYP3A4	nd	nd	nd	nd	HS/18	Itraconazole	80	11.10	Control	5.0	12.9	1.98	b	1.00	4.43	0.58	↑	Efflux inhibition	[69]
	Transporter	nd	nd	nd							DDI	5.0	57.3	1.15							
Ribociclib	Enzyme	CYP3A4 and FMO3 (minor)	-	CYP3A, CYP1A2 and CYP2E1			HS/24	Ritonavir	400	3.21	Control	1.5	30.6	0.29	d	4.20	1.79	5.28	↓	Influx inhibition	
				BCRP, OCT2, MATE1, and human BSEP -	4	nd					DDI	6.1	54.8	1.51							
	Transporter	P-gp and BCRP	nd	OATP1B1 /B3, OCT1, and MATEK2 (low)			HS/24	Rifampin	600	0.11	Control	2.1	31.5	0.44							[70,71]
											DDI	1.8	12.4	0.47	d	0.86	0.39	1.08	NS	-	
Ruxolitinib	Enzyme	CYP3A4 and CYP2C9	-	-			HS/12	Rifampin	50	0.30	Control	1.0	3.2	0.36	b	1.00	0.50	1.44	NS	-	
					1	nd	HS/14	Erythromycin	10	1.27	Control	1.5	4.1	0.58	b	0.67	1.10	0.54	↑	Efflux inhibition	[72,73]
	Transporter	-	-	-			HS/16	Ketoconazole	10	1.91	Control	1.0	3.5	0.35	b	1.00	1.60	0.83	NS	-	
											DDI	1.0	5.6	0.29							
Savolitinib	Enzyme	CYP3A4-CYP1A2-UGT1A4-UGT2B15-aldehyde	nd	nd	nd	nd	HS/18	Rifampin	600	0.39	Control	4.0	7.1	1.95							
											DDI	3.0	7.0	1.26	b	0.75	0.99	0.65	↑	Influx induction	[74]

	oxydas e																		
	Transp orter	P-gp	nd	nd			HS/15	Itraconaz ole	200	1.08	Control DDI	2.5 4.0	4.2 4.6	1.26 2.59	b	1.60	1.10	2.06	↓ Influx inhibition
		CYP3A 4,					HS /24	Itraconaz ole	25	1.49	Control DDI	1.0 1.0	8.2 14.0	0.25 0.22	b	1.00	1.71	0.86	NS -
		CYP2C 19, CYP1A 2, Enzym e CYP2C 9,	-	-															
Selum etinib		CYP2E 1, CYP3A 5 and UGT1 A1/3			4	62	HS/22	Rifampin	75	0.49	Control DDI	1.3 1.0	9.3 6.7	0.34 0.27	b	0.79	0.72	0.81	NS -
	Transp orter	P-gp and BCRP	-	OAT3															
							HS/22	Fluconaz ole	25	1.50	Control DDI	1.0 1.5	8.2 9.8	0.25 0.41	b	1.50	1.20	1.62	NS -
	Enzym e	CYP3A 4	-	-			HS caucasian /14	Rifampin	50	0.21	Control DDI	8.5 7.8	48.5 15.9	2.44 3.52	b	0.92	0.33	1.44	NS -
Sunitin ib					4	nd	HS asian/12	Rifampin	50	0.21	Control DDI	7.9 7.2	49.5 14.5	2.20 3.27	b	0.91	0.29	1.49	NS -
	Transp orter	P-gp and BCRP	-	P-gp and BCRP			HS caucasian /14	Ketocona zole	10	1.70	Control DDI	7.9 7.2	41.2 43.5	2.34 2.03	b	0.91	1.06	0.86	NS -
							HS asian/14	Ketocona zole	10	1.70	Control DDI	8.9 8.6	43.2 43.9	2.71 2.57	b	0.97	1.02	0.95	NS -
	Enzym e	CYP3A 4 and CYP1A 1	-	-	nd	nd	HS/25	Ketocona zole	1.5	1.12	Control DDI	10.0 7.5	117.0 112.0	2.29 1.62	b	0.75	0.96	0.71	NS -
Tivoza nib	Transp orter	-	nd	BCRP			HS/27	Rifampa in	1.5	0.47	Control DDI	10.0 3.0	121.0 54.0	2.27 0.61	b	0.30	0.45	0.27	↑ Influx induction
Tofacit inib	Enzym e	CYP3A 4,	-	-	3	74	HS/12	Ketocona zole	10	2.03	Control DDI	0.5 1.0	2.9 3.9	0.14 0.33	b	2.00	1.34	2.33	↓ Influx inhibition
							HS/12	Rifampin	30	0.16	Control	0.5	3.1	0.15	d	0.94	0.67	1.07	NS -

[75]

[76]

[77,78]

[79,80]

[79]

Upadacitinib	Transp orter	P-gp	nd	CYP2C19	Pgp, OCT2 and OATP1B1 (low)	1	nd	HS/22	Ciclosporin A	10	1.73	DDI Control	0.5	0.5	2.1	0.16	3.2	0.13	d	1.04	1.20	1.00	NS	-	[81,82]
	Enzyme	CYP3A4 and CYP2D6	-	-	-	-	-	HS/12	Rifampin-SD	12	1.07	DDI Control	2.9	2.8	6.5	5.9	1.18	1.24	b	0.97	0.91	1.05	NS	-	
	Transp orter	P-gp and BCRP	nd	P-gp, BCRP and OATP1B1 (weak)	-	-	-	HS/12	Rifampin	12	0.39	DDI Control	2.9	2.8	6.5	4.9	1.18	1.54	b	0.91	0.75	1.30	NS	-	
	Transp orter	P-gp and BCRP	nd	P-gp and BCRP	-	-	-	HS/11	Ketoconazole	3	1.75	DDI Control	1.1	0.9	8.5	7.4	0.29	0.23	b	0.82	0.87	0.80	NS	-	
Vemurafenib	Enzyme	CYP3A4	-	CYP1A2, 2A6, 2C9, 2C19, 2D6, and 3A4/5	-	4	nd	P/23	Rifampin	960	0.53	Control	4.0		30.0	1.05			b	1.00	0.40	1.42	NS	-	[83,84]
	Transp orter	P-gp and BCRP	-	P-gp and BCRP	-	-	-					DDI	4.0		12.0	1.49									

Bottom

Drug	Substrate	Inducer	Inhibitor	BCS	F (%)	Population	Perpetrator	Victim drug dosing (mg)	AUC- DDI/AUC- Control	Control or DDI period	Tmax	t1/2,z	MAT	MAT calculation method	Tmax ratio	t1/2,z ratio	MAT ratio	Absorption rate (ka)	Potential DDI mechanism at enterocyte level	References						
Afatinib	Enzyme	minimal	-	-	1 or 3 nd	HS/22	Ritonavir	20	1.48	Control DDI	4.0	35.9	0.99	b	1.00	0.95	1.02	NS	-	[85,86]						
	Transporter	P-gp and BCRP	nd	P-gp and BCRP		HS/22	Rifampin	40	0.66	Control DDI	6.0	32.8	1.75								b	1.00	1.10	0.97	NS	-
Baricitinib	Enzyme	CYP3A4	nd	nd	3 80	HS/18	Rifampin	10	0.66	Control DDI	1.0	7.7	0.26	b	1.00	0.62	1.18	NS	-	[87]						
	Transporter	P-gp, BCRP, OAT3 and	nd	OAT-2		HS/34	Ketoconazole	10	1.21	Control DDI	1.0	6.6	0.27								b	1.00	1.10	0.97	NS	-

MATE 2-K																					
Cabozantinib	Enzyme	CYP3A4	CYP1A1	CYP3A4, CYP2C8 and CYP2C9	nd	nd	HS/25	Rifampin	140	0.23	Control	4.0	111.0	0.74					NS	-	[88,89]
										DDI	3.0	27.7	0.74	b	0.75	0.25	1.00				
	Transporter	-	nd	P-gp			HS/27	Ketoconazole	140	1.38	Control	4.0	122.0	0.72	b	1.00	1.18	0.97			
Erdafitinib	Enzyme	CYP2C9 and CYP3A4	CYP3A4 (TD)	CYP3A4 (TD)	1	nd	HS/17	Itraconazole	4	1.34	Control	2.0	59.1	0.36					NS	-	[90,91]
											DDI	2.0	77.5	0.34	b	1.00	1.31	0.94			
	Transporter	P-gp	nd	P-gp and OCT-2																	
Gefitinib	Enzyme	CYP3A4	nd	CYP2C19, CYP2D6, CYP2C9, CYP3A4, CYP1A2 and CYP2C8	3	60	HS/24	Itraconazole	250	1.88	Control	5.0	30.7	1.40					NS	-	[92]
											DDI	5.0	38.5	1.30	b	1.00	1.25	0.93			
	Transporter	P-gp and BCRP	nd	P-gp and BCRP			HS/18	Rifampin	500	0.15	Control	3.0	33.8	0.70	b	1.00	0.61	1.16			
Ivosidenib	Enzyme	CYP3A4	CYP2B6, CYP2C8, CYP2C9, and CYP3A4	nd	2	nd	P/21	Itraconazole	250	2.69	Control	4.0	60.7	0.85					NS	-	[93,94]
											DDI	4.0	140.2	0.70	b	1.00	2.31	0.83			
	Transporter	P-gp	nd	P-gp and OAT3																	
Lorlatinib	Enzyme	CYP3A4 and UGT1A4	CYP3A4 and CYP2B6	CYP3A4	1	81	HS/12	Rifampin	100	0.15	Control	1.5	21.2	0.33					NS	-	[95]
											DDI	1.5	10.2	0.41	b	1.00	0.48	1.26			
	Transporter	P-gp	nd	nd			HS/12	Itraconazole	100	1.42	Control	1.5	23.1	0.32	b	1.00	1.29	0.94			
Neratinib	Enzyme	CYP3A4 and FMO	-	CYP3A4 and CYP2B6	2	nd	HS/22	Ketoconazole	240	4.81	Control	6.0	11.7	2.78					NS	-	[96,97]
															b	1.00	1.55	0.80			

	Transporter	nd	nd	P-gp, BCRP and OCT1					DDI	6.0	18.0	2.23						
Peficitinib	Enzyme	nd	nd	nd					Control	2.0	9.5	0.61						
	Transporter	P-gp	nd	OCT-1 and MATE1	HS/24	Verapamil	150	1.27	DDI	2.0	13.9	0.54	b	1.00	1.46	0.87	NS	-
Ponatinib		CYP3A4, CYP2C8 and CYP2D6	-	-	HS/19	Rifampin	15	0.38	Control	6.0	27.0	1.88						
	Enzyme								DDI	6.0	19.6	2.15	b	1.00	0.73	1.14	NS	-
	Transporter	P-gp and BCRP (weak)	nd	P-gp, BCRP and BSEP	HS/19	Ketoconazole	15	1.78	Control	6.0	35.3	1.70						
									DDI	6.0	37.4	1.67	b	1.00	1.06	0.98	NS	-
Sonidegib	Enzyme	CYP3A4	-	CYP2B6 and CYP2C9	HS/16	Rifampin	800	0.28	Control	2.0	124.0	0.31						
	Transporter	-	nd	BCRP	HS/15	Ketoconazole	800	2.25	Control	2.0	124.0	0.31	b	1.00	3.38	0.82	NS	-
									DDI	2.0	419.0	0.26						
Talazoparib	Enzyme	minimal	-	-	P/19	Itraconazole	0.5	1.56	Control	1.0	101.0	0.14	b	1.00	0.17	0.97	NS	-
	Transporter	P-gp and BCRP	-	-	P/17	Rifampin	1	1.00	Control	1.0	92.1	0.15						
									DDI	1.0	80.6	0.15	b	1.00	0.88	1.02	NS	-
Vandetanib	Enzyme	CYP3A4 and FMO1/3	CYP1A2, CYP2C9 and CYP3A4	CYP2D6 and CYP2C8	HS/18	Itraconazole	300	1.09	Control	5.0	209.2	0.85						
									DDI	5.0	235.5	0.83	b	1.00	1.13	0.98	NS	-
	Transporter	P-gp	nd	P-gp and OCT2	HS/12	Rifampin	300	0.60	Control	6.0	217.6	1.05	b	0.83	0.53	0.92	NS	-
Zanubrutinib	Enzyme	CYP3A4	nd	CYP2C8, CYP2C9, and CYP2C19	HS/20	Rifampin	320	0.07	Control	2.0	6.8	0.71						
		P-gp	nd	OCT-2	HS/19		320	3.78	DDI	2.0	4.8	0.83	b	1.00	0.80	1.18	NS	-
									Control	1.5	2.2	0.82						

Transp orter	Itraconaz ole	DDI	2.0	4.3	0.88	
	Ratios of oral pharmacokinetic DDI parameters (reported as interaction/control) and substrate specificities, and the inhibition or inducing potential of victim drugs for metabolic enzymes and xenobiotic transporters of 54 drugs, for which a DDI study with a perpetrator potentially interacting with a transporter (i.e., RIF n = 44, KETO n = 25 and ITRA n = 22, and miscellaneous drugs n = 10) were available. Pharmacokinetic values reported in the table are based on published average values. Top indicates the drugs (n = 40, 77 DDI studies) for which a significant variation in MAT has been evidenced during a DDI study involving either RIF (n = 33), KETO (n = 20), ITRA (n = 15) or with a miscellaneous perpetrator (n = 9). Bottom indicates the drugs (n = 14, 24 DDI studies) for which there was apparently no modification of the absorption rate (MAT ratio between 0.77 and 1.30. MAT values in bold are those considered as a relevant marker of a variation in the absorption rate: MAT ratio outside the 0.77–1.30 interval and remaining outside this interval following simulation variations in t_{max} ($\pm 10\%$). The methodology of calculation is described in detail in the Materials and Methods section. The increase in MAT ratio is shown in green and the decrease in MAT ratio in blue. The darker color is for the potential influx implication and the lighter color represents the potential efflux implication. MAT calculation method: (a) Data published: solving for MAT using multiple-dose equation; (b) Data published: solving for MAT using simple-dose equation; (c) Data missing: noncompartmental analysis to retrieve data and solving for MAT using multiple-dose equation; (d) Data missing: noncompartmental analysis to retrieve data and solving for MAT using simple-dose equation.					

4. Discussion

As shown in Table 1, the oral absolute bioavailability was only available for few drugs of our sample set (i.e., 28 on 74 molecules). The mean absolute bioavailability was quite large, with a significant variability (mean $\pm$ SD: $56 \pm 20\%$), and 15 of 28 drugs had an oral bioavailability above 50%. The application of the Lipinski “rule of 5” [110] indicated that 57% of the compounds ($n = 40$) were likely to have favorable absorption or permeation properties, bearing in mind that drugs that are substrates of transporters could be exceptions to the rule if intestinal transporters significantly influence intestinal absorption.

PCA analysis showed that the variables most contributing to Fabs were not surprisingly apparent: membrane permeability (positively correlated) and HBD (negatively correlated). However, the absolute values of correlation coefficients were somewhat small (ranging from 0.4 to 0.5, Table 2). This may result from the fact that the fraction of the drug metabolized was not integrated as a variable since it was not available.

4.1. Drug–Drug Interactions

Besides their potential to interact with CYP3A4, KETO, ITRA, and RIF also interact with transporters at the intestinal level, at least as strong inhibitors of P-gp (KETO and ITRA), and as strong inducer (RIF in multiple dosing) of P-gp. This potential double interaction at the CYP3A4 and P-gp level makes it difficult to evaluate the contribution of these mechanisms to the interaction (particularly the contribution of P-gp) in DDI studies for drugs that are substrates of both these biological systems. This was the case for half of the drugs in our sample set (40/81 drugs were substrates of both CYP3A4 and of an efflux transporter, Table 3). Furthermore, the intensity of the DDI resulting from CYP3A4 modulation should overcome the impact of P-gp modulation (or of another efflux transporter). Indeed, considering talinolol (P-gp substrate and not metabolized CYP3A4), the effect of rifampin was not so high, with a DDI-to-control AUC ratio of 0.66 [111].

When the contribution of CYP3A4 to the overall elimination of a drug is substantial, regulatory agencies have initially recommended the use of KETO and of RIF (as multiple doses), as inhibitor and inducer, respectively, in in vivo DDI studies. While KETO is a strong, selective, and reversible inhibitor of CYP3A4, concerns related to its liver toxicity have made it no longer usable in clinical trials, and several replacement inhibitors have been proposed (i.e., ITRA, ritonavir, and clarithromycin) [112]. ITRA and clarithromycin have been recommended by the FDA, and ITRA, KETO, ritonavir, and clarithromycin are currently proposed by the European Medicines Agency (EMA) [113,114]. Based on its high intensity of CYP3A4 inhibition (estimated by the fold increase in midazolam AUC), ITRA has emerged and is now widely used as a CYP3A4 reversible inhibitor, both in the gut wall and the liver, with recommendations for its clinical use [112,115]. However, there are still some debates on the use of ITRA, which is not considered as strong as KETO regarding inhibition of CYP3A, and reinstating KETO as an index inhibitor for CYP3A has been proposed [116]. The argument in favor of a stronger inhibition with KETO can be challenged in the light of our data obtained with a large panel of drugs. Indeed, the comparison of the DDI-to-control AUC ratio from KETO and ITRA DDI studies indicates that the intensity of the interaction is quite similar (Figure 4). Indeed, the mean DDI-to-control AUC ratio for KETO and ITRA was 3.73 ± 4.34 ($n = 29$) and 3.48 ± 2.90 ($n = 21$), respectively.

Based on the DDI-to-control AUC ratio, the magnitude of DDI within KETO-RIF DDI and ITRA-RIF DDI studies was related. The relationship appeared more straightforward between KETO and RIF (Figure 2B) than between ITRA and RIF (Figure 2A). The coefficients of determination indicate that the magnitude of inhibition is not so indicative of the magnitude of induction and vice versa, and this is more especially clear for ITRA. These elements question the relevance of the extrapolation of DDI to clinical situations where different inhibitors or inducers may be used in patients. This strengthens the use of modeling strategies in application files to regulatory authorities, mainly static and dynamic physiologically based pharmacokinetic (PBPK) modeling approaches, even though there

are still gaps in their prediction accuracy [117]. However, confidence of regulatory agencies in PKPB model prediction of induction is not particularly high, especially when a drug has multiple pathways and/or undergoes competing DDI mechanisms.

The magnitude of the DDI with ITRA and KETO logically decreased with the increase in oral Fabs. However, the correlation was moderate ($R^2 = 0.5835$) as a result of a rather “flat” relationship for drugs with Fabs ranging 40 to 80% (Figure 3B). The magnitude of the DDI with RIF was apparently not influenced by the intensity of Fabs with a DDI-to-control AUC ratio lower than 0.4 for drugs with oral absolute bioavailability up to 80% (Figure 3A). However, it should be noticed that a better correlation, and a lower scattering, would have been obtained by using the extent of the fraction of the drug metabolized by CYP3A4/5 (fm, CYP3A4/5) instead of Fabs that depends on both fm and of the fraction absorbed.

The magnitude of the effect of a DDI on the absorption rate of a drug (estimated by MAT ratio) appeared related to its absolute bioavailability (Figure 7). In inhibition DDI studies, the MAT ratio decreased with the decrease in Fabs. This is not unlikely, given that low Fabs can result from either a low permeability and/or from a low solubility. Indeed, the impact of the inhibition of an efflux transporter is much more significant for drugs with low intestinal permeabilities. It should be noticed that drugs with low permeability (belonging to the BCS class 3 and 4) were overrepresented in this series of drugs with variations in MAT ratio and documented Fabs. For drugs with low solubility, the impact of the inhibition of an efflux transporter is more apparent, given that the saturation of the transporter is unlikely.

In induction DDI studies, there was a trend in the MAT ratio to increase when Fabs decreased, suggesting that the lower the bioavailability, the higher the impact of an efflux transporter inhibition on the absorption rate. Similarly, inhibition DDI studies have clearly shown that the systemic exposure and the absorption rate increased with the decrease in bioavailability (Figures 3B and 7B).

The complexity of the interplay between CYP3A4 and P-gp makes it difficult to estimate the contribution of the modulation of efflux transporter to the variations in the systemic exposure. This interplay between CYP3A4 and P-gp at the intestinal level creates a functional synergy that tends to restrict the systemic exposure of oral drugs that are dual substrates. This results from reabsorption cycling, which increases the chance of a drug to be metabolized by CYP3A4, and secondly by a decrease in the intracellular concentration of drugs in the enterocytes, avoiding CYP3A4 saturation. Pharmacokinetic modeling may be used to estimate the contribution of P-gp to systemic exposure of CYP3A4 metabolized drugs. Based on induction studies with RIF in a series of drugs, including kinase inhibitors, it has been estimated that the contribution of P-gp to the decrease in AUC was 1.2-fold to 1.6-fold for CYP3A4/P-gp dual substrates in comparison to only considering CYP3A4 induction [118].

4.2. Transporters and Variations in Absorption Rate

Transporter-based DDIs can result in the modification of the rate of absorption (k_a) of drug substrates of intestinal transporters expressed on the apical side of enterocytes, leading to an increase or to a decrease in MAT depending on the nature of the transporter (efflux or influx) and of the interaction (inhibition or induction).

Within the set of 54 drugs, we found that there was apparently no modification of the absorption rate (MAT ratio between 0.77 and 1.30) for 14 drugs, with no modification in t_{max} (t_{max} ratio = 1, Table 3 bottom). This was not unlikely for cabozantinib, neratinib, and sonidegib, that were not known to be substrate of P-gp and/or BCRP, as well as for ponatinib considered as a weak P-gp/BCRP substrate (Table 3). Despite being substrates of P-gp and/of BCRP, erdafitinib and lorlatinib are BCS class 1 drugs, so their absorption is unlikely to be influenced by efflux transporters (either by bypass or by saturation of the efflux transporters by intestinal concentrations of these drugs). The absorption rate of afatinib (BCS class 1/3), of baricitinib and of gefitinib (BCS class 3), which are both substrates

of P-gp and/or BCRP, may not be influenced, as a potential saturation of the efflux transporters may occur. However, the MAT of ivosidenib and vandetanib (BCS class 2), and of talazoparib and zanubrutinib (BCS class 2/4), which are P-gp or BCRP substrates, should theoretically be sensitive to efflux transporter effects, given their low solubility. This was not the case in DDI studies with ITRA or KETO. Given that these drugs are practically insoluble and the usual recommended dose of their maximum concentration in gut lumen at neutral pH is lower than 0.21 mM (especially for talazoparib, Supplementary Material Table S2.), a saturation of efflux transporter is unlikely for these drugs. Hence, the lack of apparent effects might result from opposite effects towards efflux and uptake transporters on drug absorption.

For 40 drugs within the set (74%), a significant variation in MAT ratio was evidenced in either one or in all inhibition/induction DDI studies. For axitinib, a significant variation was evidenced in the MAT ratio in the RIF DDI study (MAT ratio = 1.70) but not in the KETO study (MAT ratio = 1.32). Considering alflutinin, a significant variation in MAT ratio was evidenced in both the RIF and KETO studies (0.53 and 2.08, respectively). As a whole, for these 40 drugs, a significant variation in MAT ratio (i.e., >1.30 or <0.77) was evidenced within 70% of the DDI studies (i.e., in 54 of all the 77 DDI studies).

Given that estimations of MAT are sensible to variations in the determinations of t_{max} , as shown in Figure 6 and to a lesser extent to variations in $t_{1/2}$, we simulated the impact of variations in t_{max} on the estimation of MAT. This allowed us, as a more conservative approach, to exclude DDIs where the MAT ratio (although outside the 0.77-to-1.30 interval) was estimated to be not reliable enough as an indicator of variation in the absorption rate (i.e., involving a DDI at the transporter level). These exclusions were observed for several drugs for which the MAT ratio was close to the limits of the 0.77–1.30 interval (Supplementary Material Figure S3.).

Within the DDI studies where the MAT ratio was considered significant ($n = 33$, resulting either from an increase or a decrease in absorption rate), we found that the induction or the inhibition of an efflux transporter (P-gp or BCRP) may explain such variations in 12 DDI studies (Figure 5). Indeed, the decrease in the absorption rate of abemaciclib (P-gp substrate) by RIF was consistent with an induction of P-gp (MAT ratio of 1.78). The induction of intestinal efflux transporters (by RIF on multiple dosing) should increase drug cycling between the enterocytes and gut lumen, thus leading to an increase in absorption time (i.e., increase in MAT). Conversely, the decrease in MAT ratio (0.61) in the KETO DDI study of acalabrutinib (P-gp and BCRP substrate) is consistent with an inhibition of intestinal efflux transporters increasing the absorption rate.

However, in 21 of the 33 DDI studies (Figure 5), potential variations in the absorption rate could not be related to a modulation in efflux transporters. For nine studies involving RIF, the decrease in MAT (suggesting an increase in absorption rate) was related either with an efflux inhibition or with an influx induction. Since RIF is not known to be an efflux inhibitor in vivo (in multiple doses), we therefore hypothesized the involvement of an influx transporter that would be induced by RIF. For 12 studies involving KETO and ITRA, an increase in MAT (suggesting a decrease in absorption rate) was observed. Such prolongation in absorption is compatible with either an efflux induction or with an influx inhibition. As KETO and ITRA are well established efflux inhibitors (and not efflux inducers) [119,120]), we therefore hypothesized that this could result from an influx inhibition. Indeed, the increase in the MAT of cobimetinib (P-gp substrate) by ITRA (MAT = 1.89, and 2-fold increase in t_{max}) indicated a decrease in absorption rate that could result from the inhibition of an influx transporter. These observations were also made with the antiplatelet agent ticagrelor and RIF (MAT and $t_{1/2}$ ratios reduced by 50%), suggesting the induction of solute carriers (SLCs) such as organic anion-transporting polypeptide transporters (OATPs/SLCOs) or a competitive inhibition of P-gp by RIF when given at the same time with the victim drug [121].

Besides OATPs, organic ion transporters belonging to the SLC22 family, i.e., organic anion transporters (OATs), organic cation transporters (OCTs), and organic

cation/carnitine transporters (OCTNs), play a major role in human physiology and in pharmacokinetics through the absorption and disposition of drugs [122]. The role of influx transporters in the uptake of oral targeted anticancer drugs is of increasing significance, and translation to humans should be made with caution since there are some discrepancies in observations from cellular models, questioning the most relevant transfected cells to be used. As a prototypic drug, imatinib uptake was successively shown to be mainly driven by OCT1 (*SLC22A1*), then by OCT2 (*SLC22A2*), and finally by OATP1A2 (*SLCO1A2*) [123,124]. In an overview, for 15 tyrosine kinase inhibitors (TKIs) as substrates and/or inhibitors of influx transporters, OATP1B1/1B3 (*SLCO1B1/1B3*) were most cited as influx transporters [123]. Furthermore, transport within enterocytes should not only be considered from the apical to basolateral side, but basolateral to apical movement may also play a crucial role in the absorption. Hence, the involvement of transporters at the basolateral interface should also be considered. Moreover, the exact location of some SLC transporters at the apical or basolateral pole of enterocytes remains debated, notably for OATP2B1 (*SLCO2B1*) [125].

Within influx intestinal transporters, transporters of organic cations should be considered given the chemical structure of our drugs on interest (i.e., bearing positive charge at pH = 7.40 for most of them). Various SLCs handle organic cations with different molecular structures: OCT1, OCT2, and OCT3 (*SLC22A3*) (These SLCs are facilitated transporters that are independent of sodium or proton gradients, i.e., exclusive facilitative diffusion transporters), while OCTN1 (*SLC22A4*) and OCTN2 (*SLC22A5*) are efficient transporters of zwitterions [126]. These transporters are involved in the absorption and/or excretion of organic cations at the intestinal, liver, and renal levels. Polyspecific OCTs (OCT1, OCT2, OCTN1, OCTN2) and ENT4 (*SLC29A4*), are involved in the enterocyte uptake of cationic drugs, and they display some overlap in substrate selectivity [127]. OCT1, OCT3, OCTN1, and OCTN2 are thought to be located at the apical membrane of the enterocytes, and are predominantly involved in the first step of organic cation absorption.

It should be noticed that there is little information on their relative abundance at the apical or basolateral membrane of enterocytes, and on their functional relevance for the uptake of individual drugs. mRNA abundance measurement showed an expression of OCTN1 and OCTN2, and a low but relevant expression of OCT1, OCT3 and the additional cation transporter multidrug and toxin extrusion protein (MATE) 2-K (*SLC47A2*), while no expression of mRNA was detected for OCT2 and MATE1 (*SLC47A1*) [126]. Intestinal abundance of OCT1 has been estimated as rather low and close to OATP2B1 expression, corresponding to 1–2% of all transporters in intestinal segments in humans [128]. Moreover, there are no data on the second step of the intestinal absorption of cationic drugs, allowing the uptake or secretion at the basolateral membrane, and cation transporters at the basolateral side of the enterocytes have not yet been identified [127].

However, the role of transporters of organic cations in the uptake of kinase inhibitors should be considered. Indeed, competitive inhibitions using intestinal Caco-2 cell experiments showed that OCT3 was involved in the uptake of gefitinib and OCT1, OCT2, and OCT3 were involved in sunitinib and crizotinib uptake, while erlotinib uptake was not modified [129]. Moreover, various TKIs have been shown to interact with OCT3 [130]. However, the analysis of drug transport with cell lines may be complicated with the intracellular accumulation evidenced in Caco-2 cells [123] that may result from lysosomal accumulation for cationic drugs [131]. Indeed, given their chemical structure of cationic hydrophobic drugs, such compounds can diffuse in the lysosome by passive diffusion and potentially via an additional mechanism using P-gp located on the lysosomal membrane [132]. Variability in intracellular distribution was shown among a set of seven PKIs, with a high uptake for sunitinib and crizotinib [129].

The role of SLCs as influx transporters is also dependent on the net charge and polarity of the drug, which may influence the relative contribution of passive diffusion and influx transport. Indeed, the intestinal absorption of sunitinib—a strong cationic drug at pH 7.40—may be more dependent on influx transport rather than passive diffusion, as

opposed to nilotinib, whose net charge at pH 7.40 is close to zero (net charge of +0.98 and +0.03 for sunitinib and nilotinib, respectively; Table 1).

When extrapolating in vitro experiments to in vivo situations for the role of organic cation transporters at the intestinal level, it should be kept in mind that immunolocalization and pharmacokinetics have suggested OCT1 expression in the basolateral membrane [133], while other results have supported an apical localization in intestinal epithelia cells [134]. Hence, further investigations are necessary to clarify the positioning of the different transporters of organic cations in the enterocytes, notably because their inhibition at the apical and at the basolateral poles should have opposite effects on the rate of drug absorption.

Within DDI studies, interaction of KETO, ITRA, and RIF with SLC uptake transporters should be considered. KETO has been shown to inhibit the standard OCT substrate ASP⁺ uptake by 82.3% in an OCT1 inhibition assay using HEK-OCT1 cells [135]. Furthermore, KETO has been identified as a potent inhibitor of OCT1 with an IC₅₀ value of 2.6 µM [136]. Moreover, KETO also inhibits OATP1B1, OATP1B3, OAT1 (*SLC22A6*), OAT3 (*SLC22A8*), OCT1, OCT2, and MATE1, with IC₅₀ values lower than 1 µM [119]. While ITRA only inhibited OCT1 (IC₅₀=0.74 µM), its metabolites (hydroxy-itraconazole and keto-itraconazole) had low IC₅₀ values for OATP1B1, OATP1B3, OCT1, and MATE1.

Another triazole antifungal agent (isavuconazole) blocks OCT1, OCT2, and MATE1 (or a combination thereof), with a rather mild inhibition intensity in vivo (1.5-fold AUC increase), using metformin as substrate [137]. The influence of isavuconazole on the absorption rate was evidenced with a decrease in MAT ratio (0.71). However, variations of ±10% in *k_a* led to a shift in MAT ratio in the 0.77–1.30 range, so it should not be considered relevant. It should be noticed that such an increase in absorption rate may be consistent with an inhibition of an OCT transporter at the basolateral level in the enterocyte.

RIF may interfere with OCT1, through mediating its upregulation at the intestinal level, as suggested in a DDI study with metformin as the victim drug [138]. The authors indicated that the DDI between RIF and metformin was not consistent with an increase in OCT1 hepatic uptake nor with an OCT2 increase in renal tubular secretion, but rather with a modification in metformin intestinal absorption kinetics, because early metformin plasma concentrations were higher after RIF treatment. However, this assumption should be ruled out because the MAT ratio that we estimated from their data was 1.0, without modification in *t_{max}* (*t_{max}* ratio = 0.98). Besides a potential upregulation of OCT1 expression, RIF has been shown to inhibit uptake of the reference OCT1 substrate ASP⁺ with a low intensity, from 15% [139] to 26.2% [135]. Hence, the role of RIF at the intestinal level may be quite complex, since upregulation of OCT1 expression and inhibition of its activity at the apical level should have opposite effects.

Within our sample set (Table 3), the decrease in MAT reported in KETO/ITRA DDI studies (*n* = 12) may be consistent a mechanism of uptake inhibition at the abovementioned apical level. The theoretical concentrations of these inhibitors in the GI tract within DDI studies lead to a value in the mM range (around 4 mM and 3 mM for KETO and ITRA) that is much higher than the reported IC₅₀ values. However, the contribution of influx transporters in the absorption of oral targeted anticancer drugs should be studied using relevant cellular models to validate our assumptions.

4.3. Limitations

The MAT methodology did not allow for an estimation of the contribution of intestinal transporter-based DDIs to the variation in drug exposure, since the vast majority of small oral molecules in cancer studies are substrates of enzymes (mostly CYP3A4) without intravenous pharmacokinetic data. Hence, the clinical relevance of intestinal transporter-based DDIs is yet to be substantiated. Improving knowledge in transporter-based DDIs at the intestinal level should contribute to a complete characterization of transporter-based DDIs at the time of initial NDA application, for which additional efforts from sponsors

are expected [140]. This would be of value to health care professionals to foster safe and effective coadministration of these small oral molecules with other co-medications.

The MAT methodology may also have some limitations for drugs with a pronounced distribution process that could be apparent after single oral dosing (i.e., distribution nose), so the equations used may lead to an error in estimation of k_a . For such drugs, the estimation of k_a from steady-state dosing should be preferred, given that at steady state there is much less distribution, and drugs behave as one-compartment model drugs.

Problems of drug solubility at the intestinal level may constitute a bias in the application of the MAT methodology. The drugs of interest were weak basic drugs that typically dissolve at low pH and potentially precipitate at elevated pH (above the pK_a), since a majority of them had a pH-dependent solubility. Hence, if the unionized form of the base form is poorly soluble, the absorption may be solubility-dependent, with a zero-order absorption rate not compatible with the assumptions that were made. Such a phenomenon may result in a decrease in the absorption rate, impacting the estimation of MAT. However, if the solubility was a limiting factor for absorption, this phenomenon may similarly impact the absorption rate in both the control and DDI arm of the studies, so variations in MAT should not appear. If we cannot rule out that solubility could be a limiting factor for absorption of such drugs, it seems apparent that this was not the case for most of the drugs, for which a variation in MAT, as well as in t_{max} , was reported in DDI studies. Furthermore, inspection of the plasma concentration–time curves did not lead to unexpected shapes, which could be related to a solubility-limited absorption.

From a biopharmaceutic point of view, the relevance of an interaction with the organic cation uptake transporter at the apical level (by induction or inhibition) for BCS Class 2 drugs may be questioned as a result of their high permeability [141], and these potential DDIs should be more relevant for BCS class 3/4 drugs [142].

SLCs handling organic cationic drugs are mainly expressed in clearance organs (The ranking based on relative gene expression in human liver: OCT1 >> OCT3 > OCT2-OCTN1, and in human kidney: OCT2-OCTN2 > OCT1-OCT3 > OCTN1 [143]), so that inhibition at these elimination organs may increase the apparent elimination half-life, which may impact MAT estimation. However, we previously showed that MAT determination was much less sensible to variations in $t_{1/2}$ than in t_{max} values, so a DDI at a systemic level is unlikely to be a confounding factor.

5. Conclusions

The MAT methodology introduced by Sodhi and Benet [9] was used to explore the involvement of transporters in DDIs at the intestinal level in a large series of small oral targeted anticancer drugs. In order to avoid an overinterpretation in variations in MAT ratio, we proposed to add a sensitivity test by simulating the influence of variations of t_{max} on the estimation of MAT ratio, to increase the robustness of the MAT ratio estimation.

A subset of DDIs was consistent with induction or inhibition of efflux transporters at the apical level (namely P-gp and/or BCRP) with well-known perpetrators (ITRA, KETO, and RIF). However, a majority of the DDIs were more consistent with a perpetrator effect on influx transporters of cationic drugs at the apical level either by inhibition of the influx by KETO or ITRA, or by an upregulation by rifampin. However, to confirm these assumptions, investigations are necessary to clarify the apical and/or basolateral positioning of different SLCs in the enterocytes, because the inhibition at the apical and at the basolateral level should have opposite effects on the rate of drug absorption. These investigations are particularly required for small oral molecules in cancers, given the complexity of their intestinal absorption, resulting in a potential interplay between the pH-dependent solubility, the intrinsic permeability, and the relative contribution of passive diffusion and of efflux/influx transporter-mediated passage that may be influenced by the percentage of ionization.

Moreover, this MAT methodology is useful to confirm the involvement of transporters in DDIs at the intestinal level, and should be used in conjunction with *in vitro*

methodologies to help understand the origin of DDIs at the intestinal level and their clinical relevance. This may help sponsors for a complete evaluation of transporter-based DDIs at the time of initial NDA approval.

Supplementary Materials: The following supporting information can be downloaded at: www.mdpi.com/article/10.3390/pharmaceutics14112493/s1, Supplementary Materials include 3 Figures and 2 Tables. Figure S1. Algorithm in Python for the estimation of k_a as a function of k_e , t_{max} . Figure S2. Distribution of the solubility at neutral pH classified according to the USP classification in a series of oral targeted anticancer drugs. Figure S3. Variations in MAT ratio following $\pm 10\%$ variations in t_{max} in a series of oral targeted anticancer drugs. Table S1. Pharmacologic class (ATC5 and ATC4 classification), initial approval indication and approval date by the FDA and the sponsor of oral targeted anticancer drugs. Table 22. Estimated concentration in the intestinal lumen at neutral pH (Igut, mM) for a series of oral targeted anticancer drugs.

Author Contributions: D.M.: data curation, software and mathematic solvation, result presentation, data analysis participation to manuscript drafting. O.F.: contribution to interpretation, participation to manuscript drafting. P.L.C.: conceptualization, data curation, result presentation, supervision, participation to manuscript drafting and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to thank Valentin Macheret (kompil Company, Paris) for the fruitful discussions on the calculation of absorption time by iterative solving of pharmacokinetic equations using Lambert function.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

ABC	ATP-binding cassette
ATC	anatomical therapeutic chemical
AUC	area under the curve
BCRP	breast cancer resistance protein
BCS	biopharmaceutics classification system
CL	clearance
DDI	drug–drug interaction
EMA	European Medicines Agency
ENT4	equilibrative nucleoside transporter
FDA	Food and Drug Administration
Fabs	absolute oral bioavailability
Fg	extent of the fraction of the dose not metabolized in the intestinal
Fh	extent of the fraction of the dose not metabolized in the liver
fm	fraction of the drug metabolized
HBD	hydrogen bond donor
HBA	hydrogen bond acceptor
IC ₅₀	half-maximal inhibitory concentration
Igut	concentration in the intestinal lumen at neutral pH
ITRA	itraconazole
IV	intravenous route
k_a	rate of absorption
k_e	apparent elimination rate
KETO	ketoconazole
Log D	logarithm of the distribution coefficient at pH 7.40
Log P	logarithm of the partition coefficient
Log S	logarithm of the solubility

MAT	mean absorption time
MATE	multidrug and toxin extrusion protein
MW	molecular weight
NDA	new drug application
OAT	organic anion transporter
OATP	organic anion transporting polypeptides transporter
OCT	organic cation transporter
OCTN	organic cation/carnitine transporter
PBPK	physiologically based pharmacokinetic
PCA	principal component analysis
P-gp	P-glycoprotein
PI	practically insoluble
PKI	protein kinase inhibitor
PMAT	plasma membrane monoamine transporter
POSA	posaconazole
PSA	polar surface area
RIF	rifampin
S	soluble
SLC	solute carriers
t _{max}	time of maximal plasma concentration
t _{1/2}	apparent terminal half-life
τ	administration interval at steady state
TPSA	topological polar surface area
USP	United States Pharmacopeia
V _{ss}	steady-state volume of distribution
VSS	very slightly soluble

References

- Carles, F.; Bourg, S.; Meyer, C.; Bonnet, P. PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials. *Molecules* **2018**, *23*, 908. <https://doi.org/10.3390/molecules23040908>.
- Gay, C.; Toulet, D.; Le Corre, P. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy. *Hematol. Oncol.* **2017**, *35*, 259–280. <https://doi.org/10.1002/hon.2335>.
- Shao, J.; Markowitz, J.S.; Di Bei, An, G. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. *J. Pharm. Sci.* **2014**, *103*, 3810–3833. <https://doi.org/10.1002/jps.24113>.
- Zhao, D.; Chen, J.; Chu, M.; Long, X.; Wang, J. Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review. *Drug Des. Devel. Ther.* **2020**, *14*, 1663–1681. <https://doi.org/10.2147/DDDT.S249098>.
- Fancher, K.M.; Pappacena, J.J. Drug interactions with Bruton's tyrosine kinase inhibitors: Clinical implications and management. *Cancer Chemother. Pharmacol.* **2020**, *86*, 507–515. <https://doi.org/10.1007/s00280-020-04137-6>.
- Sodhi, J.K.; Benet, L.Z. A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs. *Clin. Pharmacol. Ther.* **2020**, *108*, 306–315. <https://doi.org/10.1002/cpt.1828>.
- Sodhi, J.K.; Huang, C.H.; Benet, L.Z. Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. *Clin. Pharmacokinet.* **2021**, *60*, 205–222. <https://doi.org/10.1007/s40262-020-00926-7>.
- Varma, M.V.; Pang, K.S.; Isoherranen, N.; Zhao, P. Dealing with the complex drug-drug interactions: Towards mechanistic models. *Biopharm. Drug Dispos.* **2015**, *36*, 71–92. <https://doi.org/10.1002/bdd.1934>.
- Sodhi, J.K.; Benet, L.Z. The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions. *AAPS J.* **2020**, *22*, 111. <https://doi.org/10.1208/s12248-020-00469-6>.
- Mauri, A.; Consonni, V.; Pavan, M.; Todeschini, R. DRAGON software: An easy approach to molecular descriptor calculations. *MATCH. Commun. Math. Comput. Chem.* **2006**, *56*, 237–248.
- Bocci, G.; Oprea, T.I.; Benet, L.Z. State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References. *AAPS J.* **2022**, *24*, 37. <https://doi.org/10.1208/s12248-022-00687-0>.
- Corless, R.M.; Gonnet, G.H.; Hare, D.E.G.; Jeffrey, D.J.; Knuth, D.E. On the LambertW function. *Adv Comput Math* **1996**, *5*, 329–359. <https://doi.org/10.1007/BF02124750>.
- Chatzigeorgiou, I. Bounds on the Lambert Function and Their Application to the Outage Analysis of User Cooperation. *IEEE Commun. Lett.* **2013**, *17*, 1505–1508. <https://doi.org/10.1109/LCOMM.2013.070113.130972>.
- Bournez, C.; Carles, F.; Peyrat, G.; Aci-Sèche, S.; Bourg, S.; Meyer, C.; Bonnet, P. Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB. *Molecules* **2020**, *25*, 3226. <https://doi.org/10.3390/molecules25143226>.
- FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Abemaciclib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 13 December 2021).

16. Posada, M.M.; Morse, B.L.; Turner, P.K.; Kulanthaivel, P.; Hall, S.D.; Dickinson, G.L. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. *J. Clin. Pharmacol.* **2020**, *60*, 915–930. <https://doi.org/10.1002/jcph.1584>.
17. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Acalabrutinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 13 December 2021).
18. Zhou, D.; Podoll, T.; Xu, Y.; Moorthy, G.; Vishwanathan, K.; Ware, J.; Slatter, J.G.; Al-Huniti, N. Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach. *CPT Pharmacomet. Syst. Pharmacol.* **2019**, *8*, 489–499. <https://doi.org/10.1002/psp4.12408>.
19. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Alectinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 13 December 2021).
20. Morcos, P.N.; Cleary, Y.; Guerini, E.; Dall, G.; Bogman, K.; de Petris, L.; Viteri, S.; Bordogna, W.; Yu, L.; Martin-Facklam, M.; et al. Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib. *Clin. Pharmacol. Drug Dev.* **2017**, *6*, 280–291. <https://doi.org/10.1002/cpdd.298>.
21. Zhu, Y.-T.; Zhang, Y.-F.; Jiang, J.-F.; Yang, Y.; Guo, L.-X.; Bao, J.-J.; Zhong, D.-F. Effects of rifampicin on the pharmacokinetics of alflutinin, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers. *Investig. New Drugs* **2021**, *39*, 1011–1018. <https://doi.org/10.1007/s10637-021-01071-z>.
22. Heng, J.; Tang, Q.; Chen, X.; Bao, J.; Deng, J.; Chen, Y.; Zhao, J.; Zhu, S.; Liu, X.; Yang, F.; et al. Evaluation of the pharmacokinetic effects of itraconazole on alflutinin (AST2818): An open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. *Eur. J. Pharm. Sci.* **2021**, *162*, 105815. <https://doi.org/10.1016/j.ejps.2021.105815>.
23. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Avapritinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 8 December 2021).
24. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Axitinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 13 December 2021).
25. Reyner, E.L.; Sevidal, S.; West, M.A.; Clouser-Roche, A.; Freiwald, S.; Fenner, K.; Ullah, M.; Lee, C.A.; Smith, B.J. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: Implications for disposition and drug interactions. *Drug Metab. Dispos.* **2013**, *41*, 1575–1583. <https://doi.org/10.1124/dmd.113.051193>.
26. Pithavala, Y.K.; Tong, W.; Mount, J.; Rahavendran, S.V.; Garrett, M.; Hee, B.; Selaru, P.; Sarapa, N.; Klamerus, K.J. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. *Investig. New Drugs* **2012**, *30*, 273–281. <https://doi.org/10.1007/s10637-010-9511-6>.
27. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Bosutinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 8 March 2021).
28. Abbas, R.; Boni, J.; Sonnichsen, D. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. *Drug Metab. Pers. Ther.* **2015**, *30*, 57–63. <https://doi.org/10.1515/dmdi-2014-0026>.
29. Abbas, R.; Hug, B.A.; Leister, C.; Burns, J.; Sonnichsen, D. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. *J. Clin. Pharmacol.* **2011**, *51*, 1721–1727. <https://doi.org/10.1177/0091270010387427>.
30. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Brigatinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 6 July 2021).
31. Tugnait, M.; Gupta, N.; Hanley, M.J.; Sonnichsen, D.; Kerstein, D.; Dorer, D.J.; Venkatakrishnan, K.; Narasimhan, N. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. *Clin. Pharmacol. Drug Dev.* **2020**, *9*, 214–223. <https://doi.org/10.1002/cpdd.723>.
32. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Ceritinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 7 March 2021).
33. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Cobimetinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 25 May 2021).
34. Budha, N.R.; Ji, T.; Musib, L.; Eppler, S.; Dresser, M.; Chen, Y.; Jin, J.Y. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. *Clin. Pharmacokinet.* **2016**, *55*, 1435–1445. <https://doi.org/10.1007/s40262-016-0412-5>.
35. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Crizotinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 13 December 2021).
36. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Dabrafenib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 25 May 2021).
37. Suttle, A.B.; Grossmann, K.F.; Ouellet, D.; Richards-Peterson, L.E.; Aktan, G.; Gordon, M.S.; LoRusso, P.M.; Infante, J.R.; Sharma, S.; Kendra, K.; et al. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. *J. Clin. Pharmacol.* **2015**, *55*, 392–400. <https://doi.org/10.1002/jcph.437>.
38. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Dacomitinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 28 April 2021).

39. Ruiz-Garcia, A.; Giri, N.; LaBadie, R.R.; Ni, G.; Boutros, T.; Richie, N.; Kocinsky, H.S.; Checchio, T.M.; Bello, C.L. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. *J. Clin. Pharmacol.* **2014**, *54*, 555–562. <https://doi.org/10.1002/jcph.243>.
40. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Dasatinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 28 April 2021).
41. Johnson, F.M.; Agrawal, S.; Burris, H.; Rosen, L.; Dhillon, N.; Hong, D.; Blackwood-Chirchir, A.; Luo, F.R.; Sy, O.; Kaul, S.; et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. *Cancer* **2010**, *116*, 1582–1591. <https://doi.org/10.1002/cncr.24927>.
42. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Entrectinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 1 December 2021).
43. Fischer, H.; Ullah, M.; de La Cruz, C.C.; Hunsaker, T.; Senn, C.; Wirz, T.; Wagner, B.; Draganov, D.; Vazvaei, F.; Donzelli, M.; et al. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: Differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. *Neuro Oncol.* **2020**, *22*, 819–829. <https://doi.org/10.1093/neuonc/noaa052>.
44. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Fedratinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 28 April 2021).
45. Wu, F.; Krishna, G.; Surapaneni, S. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib. *Cancer Chemother. Pharmacol.* **2020**, *86*, 461–473. <https://doi.org/10.1007/s00280-020-04131-y>.
46. Zhang, Q.; Kai, J.; Zhai, Y.; Xu, N.; Shentu, J.; Zhang, Y.; Liang, Y.; Wang, Y.; Wu, L. The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers. *Br. J. Clin. Pharmacol.* **2022**, *88*, 84–90. <https://doi.org/10.1111/bcp.14926>.
47. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Glasdegib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 29 April 2021).
48. Shaik, M.N.; Hee, B.; Wei, H.; LaBadie, R.R. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. *Br. J. Clin. Pharmacol.* **2018**, *84*, 1346–1353. <https://doi.org/10.1111/bcp.13568>.
49. Tapaninen, T.; Olkkola, A.M.; Tornio, A.; Neuvonen, M.; Elonen, E.; Neuvonen, P.J.; Niemi, M.; Backman, J.T. Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction. *Clin. Transl. Sci.* **2020**, *13*, 345–351. <https://doi.org/10.1111/cts.12716>.
50. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Ibrutinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 13 December 2021).
51. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Idelalisib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 13 December 2021).
52. Koch, K.M.; Dees, E.C.; Coker, S.A.; Reddy, N.J.; Gainer, S.D.; Arya, N.; Beelen, A.P.; Lewis, L.D. The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer. *Cancer Chemother. Pharmacol.* **2017**, *80*, 1141–1146. <https://doi.org/10.1007/s00280-017-3470-y>.
53. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Lapatinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 9 February 2021).
54. Wang, Y.; Sparidans, R.W.; Li, W.; Lebre, M.C.; Beijnen, J.H.; Schinkel, A.H. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. *Br. J. Pharmacol.* **2020**, *177*, 3060–3074. <https://doi.org/10.1111/bph.15034>.
55. FDA. Center for Drug Evaluation and Research, Multi-Discipline Review of Larotrectinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 29 April 2019).
56. Shumaker, R.C.; Aluri, J.; Fan, J.; Martinez, G.; Thompson, G.A.; Ren, M. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. *Clin. Drug Investig.* **2014**, *34*, 651–659. <https://doi.org/10.1007/s40261-014-0217-y>.
57. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Lenvatinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 9 February 2019).
58. Lorusso, P.; Heath, E.I.; McGreivy, J.; Sun, Y.-N.; Melara, R.; Yan, L.; Malburg, L.; Ingram, M.; Wiezorek, J.; Chen, L.; et al. Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. *Investig. New Drugs* **2008**, *26*, 455–462. <https://doi.org/10.1007/s10637-008-9144-1>.
59. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Nilotinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 2 June 2021).
60. Tanaka, C.; Yin, O.Q.P.; Smith, T.; Sethuraman, V.; Grouss, K.; Galitz, L.; Harrell, R.; Schran, H. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. *J. Clin. Pharmacol.* **2011**, *51*, 75–83. <https://doi.org/10.1177/0091270010367428>.
61. FDA. Center for Drug Evaluation and Research, Multi-Discipline Review of Olaparib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 9 February 2019).
62. Dirix, L.; Swaisland, H.; Verheul, H.M.; Rottey, S.; Leunen, K.; Jerusalem, G.; Rolfo, C.; Nielsen, D.; Molife, L.R.; Kristeleit, R.; et al. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. *Clin. Ther.* **2016**, *38*, 2286–2299. <https://doi.org/10.1016/j.clinthera.2016.08.010>.

63. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Palbociclib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 1 December 2021).
64. Yu, Y.; Loi, C.-M.; Hoffman, J.; Wang, D. Physiologically Based Pharmacokinetic Modeling of Palbociclib. *J. Clin. Pharmacol.* **2017**, *57*, 173–184. <https://doi.org/10.1002/jcph.792>.
65. Mu, S.; Lin, C.; Skrzypczyk-Ostaszewicz, A.; Bulat, I.; Maglakelidze, M.; Skarbova, V.; Andreu-Vieyra, C.; Sahasranaman, S. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: An open-label, parallel-group phase 1 study. *Cancer Chemother. Pharmacol.* **2021**, *88*, 81–88. <https://doi.org/10.1007/s00280-021-04253-x>.
66. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Pazopanib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 3 May 2021).
67. Tan, A.R.; Gibbon, D.G.; Stein, M.N.; Lindquist, D.; Edenfield, J.W.; Martin, J.C.; Gregory, C.; Suttle, A.B.; Tada, H.; Botbyl, J.; et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. *Cancer Chemother. Pharmacol.* **2013**, *71*, 1635–1643. <https://doi.org/10.1007/s00280-013-2164-3>.
68. FDA. Center for Drug Evaluation and Research, Multi-Discipline Review of Pexidartinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 13 December 2019).
69. Liu, Y.; Zhang, Q.; Lu, C.; Hu, W. Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults. *Drug Des. Devel. Ther.* **2021**, *15*, 2485–2493. <https://doi.org/10.2147/DDDT.S312310>.
70. FDA. Center for Drug Evaluation and Research, Multi-Discipline Review of Ribociclib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 5 May 2021).
71. Samant, T.S.; Huth, F.; Umehara, K.; Schiller, H.; Dhuria, S.V.; Elmeliogy, M.; Miller, M.; Chakraborty, A.; Heimbach, T.; He, H.; et al. Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling. *Clin. Pharmacol. Ther.* **2020**, *108*, 575–585. <https://doi.org/10.1002/cpt.1950>.
72. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Ruxolitinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 3 May 2021).
73. Shi, J.G.; Chen, X.; Emm, T.; Scherle, P.A.; McGee, R.F.; Lo, Y.; Landman, R.R.; McKeever, E.G.; Punwani, N.G.; Williams, W.V.; et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. *J. Clin. Pharmacol.* **2012**, *52*, 809–818. <https://doi.org/10.1177/0091270011405663>.
74. Ren, S.; Vishwanathan, K.; Cantarini, M.; Frewer, P.; Hara, I.; Scarfe, G.; Burke, W.; Schalkwijk, S.; Li, Y.; Han, D.; et al. Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam. *Br. J. Clin. Pharmacol.* **2022**, *88*, 655–668. <https://doi.org/10.1111/bcp.14994>.
75. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Selumetinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 3 June 2021).
76. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Sunitinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 13 December 2021).
77. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Tivozanib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 3 June 2021).
78. Cotreau, M.M.; Siebers, N.M.; Miller, J.; Strahs, A.L.; Slichenmyer, W. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor. *Clin. Pharmacol. Drug Dev.* **2015**, *4*, 137–142. <https://doi.org/10.1002/cpdd.145>.
79. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Tofacitinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 27 July 2021).
80. Gupta, P.; Chow, V.; Wang, R.; Kaplan, I.; Chan, G.; Alvey, C.; Ni, G.; Ndongo, M.-N.; LaBadie, R.R.; Krishnaswami, S. Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects. *Clin. Pharmacol. Drug Dev.* **2014**, *3*, 72–77. <https://doi.org/10.1002/cpdd.71>.
81. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Upadacitinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 8 November 2021).
82. Mohamed, M.-E.F.; Jungerwirth, S.; Asatryan, A.; Jiang, P.; Othman, A.A. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. *Brit. J. Clin. Pharma.* **2017**, *83*, 2242–2248. <https://doi.org/10.1111/bcp.13329>.
83. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Vemurafenib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 26 April 2021).
84. Zhang, W.; McIntyre, C.; Forbes, H.; Gaafar, R.; Kohail, H.; Beck, J.T.; Plestina, S.; Bertran, E.; Riehl, T. Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy. *Clin. Pharmacol. Drug Dev.* **2019**, *8*, 837–843. <https://doi.org/10.1002/cpdd.643>.
85. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Afatinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 9 February 2021).
86. Wind, S.; Giessmann, T.; Jungnik, A.; Brand, T.; Marzin, K.; Bertulis, J.; Hocke, J.; Gansser, D.; Stopfer, P. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. *Clin. Drug Investig.* **2014**, *34*, 173–182. <https://doi.org/10.1007/s40261-013-0161-2>.

87. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Baricitinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 27 April 2021).
88. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Cabozantinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 27 April 2021).
89. Nguyen, L.; Holland, J.; Miles, D.; Engel, C.; Benrimoh, N.; O'Reilly, T.; Lacy, S. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. *J. Clin. Pharmacol.* **2015**, *55*, 1012–1023. <https://doi.org/10.1002/jcph.510>.
90. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Erdafitinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 9 February 2021).
91. Poggesi, L.; Li, L.Y.; Jiao, J.; Hellemans, P.; Rasschaert, F.; de Zwart, L.; Snoeys, J.; Meulder, M. de; Mamidi, R.N.V.S.; Ouellet, D. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study. *Eur. J. Drug Metab. Pharmacokinet.* **2020**, *45*, 101–111. <https://doi.org/10.1007/s13318-019-00581-9>.
92. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Gefitinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 16 May 2021).
93. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Ivosidenib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 26 April 2021).
94. Dai, D.; Yang, H.; Nabhan, S.; Liu, H.; Hickman, D.; Liu, G.; Zacher, J.; Vutikullird, A.; Prakash, C.; Agresta, S.; et al. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. *Eur. J. Clin. Pharmacol.* **2019**, *75*, 1099–1108. <https://doi.org/10.1007/s00228-019-02673-6>.
95. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Lorlatinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 2 June 2021).
96. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Neratinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 21 June 2021).
97. Abbas, R.; Hug, B.A.; Leister, C.; Burns, J.; Sonnichsen, D. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. *Br. J. Clin. Pharmacol.* **2011**, *71*, 522–527. <https://doi.org/10.1111/j.1365-2125.2010.03845.x>.
98. Zhu, T.; Howieson, C.; Wojtkowski, T.; Garg, J.P.; Han, D.; Fisniku, O.; Keirns, J. The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor. *Clin. Pharmacol. Drug Dev.* **2017**, *6*, 548–555. <https://doi.org/10.1002/cpdd.344>.
99. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Ponatinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 4 May 2021).
100. Narasimhan, N.I.; Dorer, D.J.; Davis, J.; Turner, C.D.; Sonnichsen, D. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. *Clin. Pharmacol. Drug Dev.* **2015**, *4*, 354–360. <https://doi.org/10.1002/cpdd.182>.
101. Narasimhan, N.I.; Dorer, D.J.; Niland, K.; Haluska, F.; Sonnichsen, D. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. *J. Clin. Pharmacol.* **2013**, *53*, 974–981. <https://doi.org/10.1002/jcph.109>.
102. Einolf, H.J.; Zhou, J.; Won, C.; Wang, L.; Rebello, S. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients. *Drug Metab. Dispos.* **2017**, *45*, 361–374. <https://doi.org/10.1124/dmd.116.073585>.
103. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Sonidegib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 3 June 2021).
104. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Talazoparib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 3 June 2021).
105. Elmeliegy, M.; Láng, I.; Smolyarchuk, E.A.; Chung, C.-H.; Plotka, A.; Shi, H.; Wang, D. Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours. *Br. J. Clin. Pharmacol.* **2020**, *86*, 771–778. <https://doi.org/10.1111/bcp.14178>.
106. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Vandetanib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 26 April 2021).
107. Martin, P.; Oliver, S.; Robertson, J.; Kennedy, S.-J.; Read, J.; Duvauchelle, T. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. *Drugs R D* **2011**, *11*, 37–51. <https://doi.org/10.2165/11586980-000000000-00000>.
108. FDA. Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s) of Zanubrutinib. Available online: <https://www.accessdata.fda.gov/scripts/cder/daf/> (accessed on 16 March 2021).
109. Mu, S.; Tang, Z.; Novotny, W.; Tawashi, M.; Li, T.-K.; Ou, Y.; Sahasranaman, S. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. *Cancer Chemother. Pharmacol.* **2020**, *85*, 391–399. <https://doi.org/10.1007/s00280-019-04015-w>.
110. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* **2001**, *46*, 3–26. [https://doi.org/10.1016/s0169-409x\(00\)00129-0](https://doi.org/10.1016/s0169-409x(00)00129-0).

111. Zschiesche, M.; Lemma, G.L.; Klebingat, K.-J.; Franke, G.; Terhaag, B.; Hoffmann, A.; Gramatté, T.; Kroemer, H.K.; Siegmund, W. Stereoselective disposition of talinolol in man. *J. Pharm. Sci.* **2002**, *91*, 303–311. <https://doi.org/10.1002/jps.10054>.
112. Liu, L.; Bello, A.; Dresser, M.J.; Heald, D.; Komjathy, S.F.; O'Mara, E.; Rogge, M.; Stoch, S.A.; Robertson, S.M. Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies. *J. Clin. Pharmacol.* **2016**, *56*, 143–151. <https://doi.org/10.1002/jcph.562>.
113. FDA. Clinical Drug Interaction Studies—Study Design, Data Analysis, and Clinical Implications. Guidance for Industry [Online]. Available online: <https://www.fda.gov/media/134581/download> (accessed on 24 January 2020).
114. EMA. Guideline on the Investigation of Drug Interactions [Online]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions_en.pdf (accessed on 24 January 2020).
115. Chen, Y.; Cabalu, T.D.; Callegari, E.; Einolf, H.; Liu, L.; Parrott, N.; Peters, S.A.; Schuck, E.; Sharma, P.; Tracey, H.; et al. Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model. *CPT Pharmacomet. Syst. Pharmacol.* **2019**, *8*, 685–695. <https://doi.org/10.1002/psp4.12449>.
116. Rohr, B.S.; Mikus, G. Proposal of a Safe and Effective Study Design for CYP3A-Mediated Drug–Drug Interactions. *J. Clin. Pharmacol.* **2020**, *60*, 1294–1303. <https://doi.org/10.1002/jcph.1622>.
117. Hariparsad, N.; Ramsden, D.; Taskar, K.; Badée, J.; Venkatakrishnan, K.; Reddy, M.B.; Cabalu, T.; Mukherjee, D.; Rehmel, J.; Bolleddula, J.; et al. Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective. *Clin. Pharmacol. Ther.* **2022**, *112*, 770–781. <https://doi.org/10.1002/cpt.2503>.
118. Pan, X.; Yamazaki, S.; Neuheoff, S.; Zhang, M.; Pilla Reddy, V. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates. *CPT Pharmacomet. Syst. Pharmacol.* **2021**, *10*, 1485–1496. <https://doi.org/10.1002/psp4.12717>.
119. Vermeer, L.M.M.; Isringhausen, C.D.; Ogilvie, B.W.; Buckley, D.B. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. *Drug Metab. Dispos.* **2016**, *44*, 453–459. <https://doi.org/10.1124/dmd.115.067744>.
120. Floerl, S.; Kuehne, A.; Hagos, Y. Functional and Pharmacological Comparison of Human, Mouse, and Rat Organic Cation Transporter 1 toward Drug and Pesticide Interaction. *Int. J. Mol. Sci.* **2020**, *21*, 6871. <https://doi.org/10.3390/ijms21186871>.
121. Liu, S.; Sodhi, J.K.; Benet, L.Z. Analyzing Potential Intestinal Transporter Drug–Drug Interactions: Reevaluating Ticagrelor Interaction Studies. *Pharm. Res.* **2021**, *38*, 1639–1644. <https://doi.org/10.1007/s11095-021-03105-w>.
122. Yee, S.W.; Giacomini, K.M. Emerging Roles of the Human Solute Carrier 22 Family. *Drug Metab. Dispos.* **2022**, *50*, 1193–1210. <https://doi.org/10.1124/dmd.121.000702>.
123. Da Silva, C.G.; Honeywell, R.J.; Dekker, H.; Peters, G.J. Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters. *Expert Opin. Drug Metab. Toxicol.* **2015**, *11*, 703–717. <https://doi.org/10.1517/17425255.2015.1006626>.
124. Blanc Mettral, J.; Faller, N.; Cruchon, S.; Sottas, L.; Buclin, T.; Schild, L.; Choong, E.; Nahimana, A.; Decosterd, L.A. Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH. *Drug Metab. Lett.* **2019**, *13*, 102–110. <https://doi.org/10.2174/1872312813666190207150207>.
125. Kinzi, J.; Grube, M.; Meyer Zu Schwabedissen, H.E. OATP2B1—The underrated member of the organic anion transporting polypeptide family of drug transporters? *Biochem. Pharmacol.* **2021**, *188*, 114534. <https://doi.org/10.1016/j.bcp.2021.114534>.
126. Koepsell, H. Organic Cation Transporters in Health and Disease. *Pharmacol. Rev.* **2020**, *72*, 253–319. <https://doi.org/10.1124/pr.118.015578>.
127. Koepsell, H. Update on drug–drug interaction at organic cation transporters: Mechanisms, clinical impact, and proposal for advanced in vitro testing. *Expert Opin. Drug Metab. Toxicol.* **2021**, *17*, 635–653. <https://doi.org/10.1080/17425255.2021.1915284>.
128. Drozdik, M.; Busch, D.; Lapczuk, J.; Müller, J.; Ostrowski, M.; Kurzawski, M.; Oswald, S. Protein Abundance of Clinically Relevant Drug Transporters in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens. *Clin. Pharmacol. Ther.* **2019**, *105*, 1204–1212. <https://doi.org/10.1002/cpt.1301>.
129. Honeywell, R.J.; Hitzler, S.; Kathmann, I.; Peters, G.J. Transport of six tyrosine kinase inhibitors: Active or passive? *ADMET DMPK* **2016**, *4*, 23. <https://doi.org/10.5599/admet.4.1.275>.
130. Alim, K.; Bruyère, A.; Lescoat, A.; Jouan, E.; Lecureur, V.; Le Vée, M.; Fardel, O. Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. *Expert Opin. Drug Metab. Toxicol.* **2021**, *17*, 259–271. <https://doi.org/10.1080/17425255.2021.1862084>.
131. de Klerk, D.J.; Honeywell, R.J.; Jansen, G.; Peters, G.J. Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. *Cancers* **2018**, *10*, 503. <https://doi.org/10.3390/cancers10120503>.
132. Scherrmann, J.M. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine–Azithromycin Combination in COVID-19 Therapy. *AAPS J.* **2020**, *22*, 86. <https://doi.org/10.1208/s12248-020-00465-w>.
133. Zhou, S.; Zeng, S.; Shu, Y. Drug–Drug Interactions at Organic Cation Transporter 1. *Front. Pharmacol.* **2021**, *12*, 628705. <https://doi.org/10.3389/fphar.2021.628705>.

134. Han, T.K.; Everett, R.S.; Proctor, W.R.; Ng, C.M.; Costales, C.L.; Brouwer, K.L.R.; Thakker, D.R. Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. *Mol. Pharmacol.* **2013**, *84*, 182–189. <https://doi.org/10.1124/mol.112.084517>.
135. Ahlin, G.; Karlsson, J.; Pedersen, J.M.; Gustavsson, L.; Larsson, R.; Matsson, P.; Norinder, U.; Bergström, C.A.S.; Artursson, P. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. *J. Med. Chem.* **2008**, *51*, 5932–5942. <https://doi.org/10.1021/jm8003152>.
136. Chen, E.C.; Khuri, N.; Liang, X.; Stecula, A.; Chien, H.-C.; Yee, S.W.; Huang, Y.; Sali, A.; Giacomini, K.M. Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1). *J. Med. Chem.* **2017**, *60*, 2685–2696. <https://doi.org/10.1021/acs.jmedchem.6b01317>.
137. Yamazaki, T.; Desai, A.; Goldwater, R.; Han, D.; Lasseter, K.C.; Howieson, C.; Akhtar, S.; Kowalski, D.; Lademacher, C.; Rammelsberg, D.; et al. Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects. *Clin. Pharmacol. Drug Dev.* **2017**, *6*, 66–75. <https://doi.org/10.1002/cpdd.280>.
138. Cho, S.K.; Yoon, J.S.; Lee, M.G.; Lee, D.H.; Lim, L.A.; Park, K.; Park, M.S.; Chung, J.-Y. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. *Clin. Pharmacol. Ther.* **2011**, *89*, 416–421. <https://doi.org/10.1038/clpt.2010.266>.
139. Jensen, O.; Gebauer, L.; Brockmöller, J.; Dücker, C. Relationships between Inhibition, Transport and Enhanced Transport via the Organic Cation Transporter 1. *Int. J. Mol. Sci.* **2022**, *23*, 2007. <https://doi.org/10.3390/ijms23042007>.
140. Younis, I.R.; Manchandani, P.; Hassan, H.E.; Qosa, H. Trends in FDA Transporter-Based Post-Marketing Requirements and Commitments Over the Last Decade. *Clin. Pharmacol. Ther.* **2022**, *112*, 635–642. <https://doi.org/10.1002/cpt.2701>.
141. Estudante, M.; Morais, J.G.; Soveral, G.; Benet, L.Z. Intestinal drug transporters: An overview. *Adv. Drug Deliv. Rev.* **2013**, *65*, 1340–1356. <https://doi.org/10.1016/j.addr.2012.09.042>.
142. Wu, C.-Y.; Benet, L.Z. Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. *Pharm. Res.* **2005**, *22*, 11–23. <https://doi.org/10.1007/s11095-004-9004-4>.
143. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A.-L.; Karlsson, J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. *Drug Metab. Dispos.* **2007**, *35*, 1333–1340. <https://doi.org/10.1124/dmd.107.014902>.